# Effects of statins on brain tumors: a review

Amir R. Afshari[1], Hamid Mollazadeh[1,2], Neil C. Henney[3], Tannaz Jamialahmadi,[4,5] Amirhossein Sahebkar[6,7,8,9]

[1]Department of Physiology and Pharmacology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran

[2]Natural Products and Medicinal Plants Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran

[3]Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK

[4]Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran

[5]Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

[6]Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

[7]Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

[8]Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

[9]School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

***Corresponding Author**

Amirhossein Sahebkar, Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran. Tel: +985138002299; Fax: +985138002287; E-mail: sahebkara@mums.ac.ir; amir_saheb2000@yahoo.com

**Running Title:** Statins and brain tumors

## Abstract

Evidence from preclinical studies suggests that the competitive HMG-CoA reductase (HMGCR) inhibitors universally known as 'statins,' in addition to being powerful drugs that reduce cholesterol and improve cardiovascular risk, also have promising antitumor properties. Statins appear to enhance the treatment outcome of various cancers before and concurrent with other cancer treatment interventions. Glioblastoma multiforme (GBM), a particularly invasive cerebral tumor associated with high mortality, holds a poor median overall survival (OS) of around one year after surgical resection followed by concurrent radiation and chemotherapy. Recently, statins have increasingly appeared as potential adjuvant drugs for the treatment of GBM because of their potential to suppress cell growth, survival, migration, metastasis, inflammation, angiogenesis, and promote apoptosis during both *in vitro* and *in vivo* studies. However, the clinical outcomes of statins on the survival of patients with GBM are still controversial. This study aims to review and address some of the documented effects of statin drugs when focusing entirely on cancer treatment, especially GBM, including concurrent statin therapy with chemotherapeutic agents.

***Keywords:*** Statin; Cholesterol; Antitumor; Glioblastoma multiforme; Apoptosis

## 1. Introduction

Patients of glioblastoma multiforme (GBM), one of the most invasive cerebrum tumors, have an expected lifespan of 12–18 months following diagnosis despite various treatment modalities, including maximal safe surgical resection, irradiation, and chemotherapy with temozolomide (TMZ) [1, 2]. While substantial progress has been made in understanding GBM pathogenesis, median patient overall survival (OS) has improved little throughout the last three decades [3]. Hence, owing to the poor prognosis of this malignant disease [4], the research emphasis has switched to identify and evaluate promising potential treatment adjuvants.

The mevalonate process may generate essential molecules, namely non-sterol isoprenoids, including dolichol, ubiquinol, farnesol, and geranylgeraniol, in addition to eventually allowing cholesterol to develop [5]. Such isoprenoids are the lipid anchors for several proteins that have been described initially as oncogenes, including the specific GTPases Ras, Rac1, and Rho, and that blocking this pathway may significantly impact essential cellular processes [6]. Statins are very well known and widely prescribed lipid-lowering agents, subclassified by origin as natural or fungal-derived [simvastatin, pravastatin, and lovastatin] and synthetic [atorvastatin, rosuvastatin, fluvastatin, cerivastatin, and pitavastatin]. At the molecular level, statins differ in their capability to inhibit the highly rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (HMGCR). In turn, they block geranylgeranyl diphosphate (GGPP) and farnesyl diphosphate (FPP) synthesis, which are necessary to trigger several proteins through prenylation, including Rho, Rac1, and Ras (small G proteins) [7-9]. Alteration of the prenylation of Ras by statins regulates cell development, survival, migration, invasion, metastasis, and apoptosis through the downstream signaling pathways. Several studies have shown that statins like atorvastatin exert anticancer activity via inhibiting the mevalonate pathway [10], both *in vitro* and *in vivo* [11]. The efficacy of statins as cancer treatments in monotherapy and combination with

existing chemotherapeutic agents has been evaluated in cancer patients [12]. For example, a case-control analysis documented a relatively low risk of colorectal cancer associated with the use of statins for at least five years [13]. Another case-control report has found that the risk of prostate cancer may be reduced in patients who take statins [14]. Several research studies have shown that statins activate the programmed death of the cells inside a subset of tumor-derived cell lines, suggesting a susceptibility for statin-specific apoptosis *in vivo* [15].

The mevalonate pathway and specifically HMGCR play a vital sinister role in the development of GBM. In a clinical GBM sample, the upregulation of HMGCR was observed [16]. Statins, also in GBM, could contribute to apoptosis by suppressing extracellular signal-regulated kinase (ERK) 1/2 and triggering protein kinase B (Akt), and by antiapoptotic protein Bcl-2 downregulation [17-19]. In preclinical GBM studies, statins could inhibit the invasion, migration, and differentiation of GBM cells by Ras/Rho-prenylation [20]. Although preclinical data support statin antitumor involvement in GBM, only a few clinical trials have established a connection between statins and GBM survival. In one clinical study, it has been reported that long-term statin therapy may be beneficial in GBM patients [21]. This review discusses the impact of statins and their potential molecular anticancer frameworks in preclinical studies and critically describes data on the role of statins in treating GBM.

## 2. Potential antitumor mechanisms of statins

Interest continues to increase regarding the potential uses and associated mechanisms of statins beyond the reduction of cholesterol, as several studies have demonstrated that some cholesterol-independent consequences of statins may have a positive effect on various diseases [22]. These benefits include increased endothelial and/or atherosclerotic plaque stability, with

immunomodulatory, neuroprotective, and anti-inflammatory properties, as well as anticancer effects [23]. The cytoprotective consequences of statins can be exemplified by the fact that statins often inhibit the synthesis of several other metabolites, including isoprenoids that are used to alter several proteins (Ras, Rac1, and RhoA) after transcription [24]. These substances are essential for various cellular essential functions and can provide an explanation for the pharmacological anticancer effects of non-cholesterol-based statins (Fig. 1) [25].

In cancer, statins may have inhibitory effects on the post-translation prenylation of members of the small Rho GTPase-protein family, blocking their translocation to the plasma membrane, which results in reduced cell proliferation and the induction of apoptosis. However, according to a study by Matzno *et al.*, statin-induced apoptosis in muscle tissue was initiated by farnesylated Ras protein depletion, and not geranylated Rho protein [26]. Statins also suppress dose-dependent tumor growth, invasiveness, and metastatic lesion formation, especially in highly invasive tumor cell lines [27]. The inhibition of isoprenoids synthesis mediated by statins also contributes to apoptosis induction and prevents the development of the cell cycle in different types of cancer cells [28]. In many cancers, including melanoma, extrahepatic cholangiocarcinoma, pancreatic adenocarcinoma, non–muscle-invasive bladder cancer, hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and in breast, colorectal, liver, lung, and prostate cancers, the effects of statins on cancer risk, recurrence and survival have been confirmed in preclinical and clinical studies [29-37]; however, some of the large-scale reviews, including systematic review and meta-analysis, have not clearly shown any beneficial impact of statins against cancer [38-40]. Recently, a major cohort study of around 200,000 individuals has reported a positive impact on the survival rates of patients with different types of cancer through long-term statin use [41]. A meta-analysis in 2017 showed that although statins as a drug class may decrease the mortality of

breast cancer patients, the antitumor effect differs by statin type and is also influenced by time to follow up [42]. For instance, in patients with breast cancer, lipophilic statins, like simvastatin, atorvastatin, and fluvastatin, have shown a significant protective role. At the same time, all-cause mortality was slightly increased by hydrophilic statins, like rosuvastatin and pravastatin [43]. However, numerous studies have reported that statin users showed more prolonged medium relapse-free survival and maintained a decreased risk of recurrence in young breast cancer patients [44, 45]. Their possible anticancer mechanisms include tumor cell proliferation inhibition (by mitigating the phosphatidylinositol-3-kinase [PI3K]/Akt/mammalian target of rapamycin [mTOR] signaling pathway), cell cycle arrest promotion, apoptotic cell death induction, and cell migration/invasion/metastasis inhibition [46]. *In vivo* studies have also been performed with promising results. The tumor scale of xenografts originating from breast cancer and prostate cancer cells in mice has been shown to decrease following treatment by simvastatin [47]. In the next sections of this review, we discuss the anticancer impacts of statins, including inhibition of growth caused by cell cycle arrest and apoptosis induction, potential metastatic reduction, inhibition of angiogenesis, and the suppression of tumor differentiation.

### *2.1. Apoptosis initiation*

A sequence of genetic modifications can be seen as a result of the transition of the normal cell into a malignant cell; therefore, induction of programmed cell death or apoptosis is one of the essential mechanisms employed in the treatment of malignancies [48]. Apoptosis happens via two pathways - intrinsic and extrinsic - and statins can significantly impact both [49]. According to one study, statins activate the mitochondrial pathway of apoptosis in various cancer cells [50]. One of the paths hypothesized for the impact of statins on cancer is to modify the expression levels of the pro- and anti-apoptotic Bcl-2 protein family (intrinsic pathway) [51]. Pharmacologically, statin-

inducing apoptotic pathways are likely regulated by altered Ras or RhoA prenylation, the cytosolic release of the second mitochondria-derived activator of caspases (Smac/DIABLO), and reduction of mitochondrial membrane potential ($\Delta\psi m$) [50]. Several findings have shown that statins decrease the anti-apoptotic protein Bcl-2 expression levels, contributing to apoptosis induction through caspases-2/-3/-8/-9 and p53 activation, increases in Bax and Bim, as well as poly (ADP-ribose) polymerase (PARP) cleavage and DNA laddering [52-54]. Consistently, it has been found that simvastatin can activate caspases-3/-7/-9, which induces apoptosis by depleting isoprenoids as precursors for prenylation of small Rho GTPases in different human cancer cell lines [55, 56]. The data from the study by Hoque *et al.* have revealed that simvastatin and lovastatin effectively reduce the cell viability of prostate cancer cells (PC3, DU145, and LnCap) by triggering apoptosis through caspases-3/-8/-9 activation [57]. Also, Cafforio *et al.* have shown the caspase-dependent apoptotic effects of the statins on myeloma tumor cells [50]. In line with these findings, Fujiwara *et al.* have indicated that statins promote cell death by increasing the activation of caspases-3/-9, inducing Bim expression, and arresting the cell cycle at the G1 phase, and by decreasing the $\Delta\psi m$ through inhibition of Ras/ERK and Ras/mTOR pathways, supporting the argument that statins may be promising antitumor drugs [58].

In addition to the intrinsic pathway, statins can activate the extinct death receptor (DR) pathway by upregulating Fas, the Fas-ligand (Fas-L) receptor [59]. It has been shown that statins stimulate *in vitro* the membrane Fas-L expression and lymphocyte apoptosis through the RhoA/Rho-associated protein kinase (ROCK) pathway in murine melanoma cells [60]. In line with this, simvastatin treatment results in increased mRNA and protein expression of molecules like the tumor necrosis factor (TNF) and Fas-L in mediating prostate cancer cell apoptosis [61]. In Fig. 2, we summarized the potential apoptosis-inducing mechanisms of statins in different cancer cells,

and some of the critical apoptotic effects of statins on various cancer cell lines are outlined in Table 1.

### *2.2. Cytostatic effects of statins*

As stated in the previous section, statins inhibit the production of mevalonate, a precursor of cholesterol, which is catalyzed by HMGCR [62]. Overexpression of mevalonate has been correlated with cell survival and tumor growth [51, 63]. Statins suppressing the mevalonate pathway inhibit GGPP and FPP synthesis and, consequently, several functional proteins, such as RhoA, which is essential for the post-translation of specific cell cycle regulatory proteins [64]. In particular, simvastatin targets RhoA geranylgeranylation and its translocation to the cell membrane, where it interferes with downstream effectors to regulate the cell cycle [65]. It has been proven that statins have an antiproliferative and pro-apoptotic effect in cancer cells by regulating the cell cycle [66]. Different experiments have demonstrated that statins disrupt the G1 or S phases, thus inducing *in vitro* apoptosis of several cancer cells [54, 67-69]. Mechanistically, the up-regulation of cyclin-dependent kinase (CDK, p21, and p27) inhibitors and the downregulation of cycle-dependent factors is mediated through statin-induced cell cycle arrest [70].

Simvastatin has been found to provoke the death of breast cancer cells and disabling the signaling pathways of PI3K/Akt and mitogen-activated protein kinase (MAPK)/ERK [56, 71]. Conversely, the outcomes from Wang *et al.* in bladder cancer cells have indicated that, by reducing the abundance of the protein involved in the phase regulation of the G0- and G1-phase, simvastatin had no significant impact on apoptosis and cleaved caspase-3/-9, but did inhibit proliferation and triggered cell cycle arrest in the G0/G1-phase (CDK4, CDK6, and cyclin D1) through PPAR-γ activation [72]. This shows that simvastatin modulates cell cycle-regulating genes (TP53, CDKN1A, and CDK1). It inhibits the proliferation of the cell cycle, as demonstrated by higher

cell percentages in the G0/G1-phases and lower cell percentages in the S-phase [73]. Ma *et al.* further showed that simvastatin reduces the expression of cyclin D1 and CDK4 and increases p27 expression in nasopharyngeal carcinoma cells during the G1-phase [74].

The effectiveness of novel simvastatin derivatives has been shown to cause the arrest of the S-phase and apoptosis in prostate cancer [75]. Recently, it has been demonstrated that rosuvastatin polymeric nanocapsules are superior in their anticancer activity on human liver (HepG2) cancer cells through enhanced apoptosis and cell cycle arrest at the G2/M-phase, which has further highlighted their potential in the treatment of hepatic cancer [76]. The cytostatic effects of statins on the cell cycle progression in various cancer cells are summarized in Table 2.

### *2.3. Chemotherapeutic activity potentiation*

Preclinical studies have shown that adjuvant statin utilization can potentially improve biological activity and minimize the resistance of standard anticancer treatment [55]. In this regard, statins, as well as aspirin and metformin, are associated with increased downstaging of rectal tumors and, thus, may have a role as adjuncts to neoadjuvant treatment, highlighting a potentiating effect of statins against rectal cancer [77]. Margaret *et al.* have shown that statin (atorvastatin and simvastatin) and metformin use is associated with improved OS in pancreatic ductal adenocarcinoma patients. In this study, statin, as well as metformin use, was associated with better OS in affected patients [78], suggesting that the combination of these drugs could be beneficial in the clinical setting as an adjuvant to traditional chemotherapeutic agents.

Tosedostat, an aminopeptidase inhibitor drug, has shown positive efficacy in acute myeloid leukemia (AML). Cloos *et al.* showed that some statins (fluvastatin, pravastatin, lovastatin, and simvastatin) potentiate the antitumor activity of CHR2863, a close structural analog of tosedostat, in U937 AML cells. Increased apoptosis induction and cell cycle arrest were also corroborated in

the synergy of CHR2863 with statins, which increases sub-G1 fraction [79]. A retrospective review of persistent and refractory AML cases, treated with combination therapy, including tosedostat, showed a therapeutic advantage for patients with statin users. AML patients taking both statins and tosedostat had a 50% probability of six months survival compared to three months probability of survival for patients not taking statins [80].

Pałko-Łabuz *et al.* have shown that mixed utilization statins (simvastatin and mevastatin, 0-120 μM) and hydroxy-flavones (50 μM) contributed to an improved inhibition of cell growth and more robust apoptosis than statin use alone. In drug-resistant cells, the combination of statins with flavones produced a more significant decrease in doxorubicin resistance than the effect observed with statins alone [81].

Statins increase low-density lipoprotein receptor (LDLR) expression, producing a prominent source for LDLR degradation and additionally upregulate proprotein convertase subtilisin/kexin type 9 (PCSK9) [82]. This provides a negative feedback response that reduces the impact of statins on lipid reduction; the design of PCSK9 inhibitors can, therefore, enhance the lipid-reducing functions of statins [83]. To date, multiple clinical studies were conducted to determine the potential relation between PCSK9 inhibitors and cancer risk [84]. Silibinin A (the principal active constituent of silymarin) therapy has been shown to suppress PCSK9 expression in HepG2 cells by reducing the activity of the PCSK9 promoter. Silibinin A specifically antagonizes the statin-induced phosphorylation pathway of p38 MAPK, indicating that silibinin A may be identified as a novel inhibitor of PCSK9 that can improve the efficacy of statin therapy [85]. Furthermore, fluphenazine and its two derivatives, along with simvastatin, enhance the cytotoxicity of doxorubicin (0–35 μM) in comparison to treatment with phenothiazine derivatives in the treatment of doxorubicin-resistant colon cancer cells. Also, Środa-Pomianekthe *et al.* have demonstrated that

the treatment of colon cancer cells with simvastatin improves the anti-multidrug resistance (MDR), anti-inflammatory, and pro-apoptotic effects of phenothiazines [86]. Some of the combinational strategies-based statins against various cancer models are shown in Table 3.

### *2.4. Antimetastatic effects of statins*

Cancer metastasis is the primary cause of cancer mortality rates, responsible for approximately 90% of cancer-related deaths [87]. Since statins can inhibit the outgrowth of metastatic tumors, they can be viewed as long term adjuvant medications to postpone clinical crises and reduce mortality in affected patients [88]. Transformed malignant cells depend primarily on the mevalonate pathway for lipid moiety, which is essential for cell growth, cell adhesion, cell cycle development, and cell signaling [89]. A wide variety of tumors have demonstrated the enhanced activity of the mevalonate pathway; therefore, inhibition of the mevalonate pathway with inhibitors of HMGCR will cause a decrease in mevalonate and its products to have a significant inhibitory impact on cancer cell metastasis [90]. Given the function of Rho, its synthesis inhibition will mitigate cell proliferation and thereby repress the initiation of the tumor [91]. Since tumors include a group of cancer stem cells that can trigger metastatic dissemination, Rho activity might, in turn, be linked to cancer stem cell activity [92]. For instance, atorvastatin (0-250 μM) exhibits anti-tumorigenic and antimetastatic effects in ovarian cancer cells *in vitro* [93], and simvastatin and atorvastatin both cause a concentration-dependent decline in colony-forming ability and cell migration of human cholangiocarcinoma cells [94]. Also, simvastatin significantly induces DNA damage and reduces cell adhesion and invasion through the Akt/MAPK signaling cascade in ovarian cancer cells [95]. The Cysteine-rich inducer 61 (Cyr61) matricellular protein is correlated with the invasion of tumors and induction of tumorigenesis in many *in vivo* malignancies. This facilitates the dissemination of tumors, chemotaxis, angiogenesis, and cellular adhesion. s ht n

,eragerChen *et al.* have shown that simvastatin (0–20 μM) causes migration inhibition through the abrogation of Cyr61 protein expression in malignant human anaplastic thyroid cancer cells [96].

An effective mechanism of cancer metastasis is the epithelial-to-mesenchymal transformation (EMT), which is a dynamic multi-gene programming cycle [97]. Lipophilic statins have been found to antagonistically change the EMT pathways of signaling stem-like cells in breast cancer by inhibiting the mevalonate pathway [98]. Atorvastatin partially inhibits the EMT process induced by transforming growth factor (TGF)-β1 by attenuating the upregulation of SphK1 and inhibiting cell migration and actin filament remodeling in non-small cell lung cancer cells [99]. Also, carcinostatic impacts of atorvastatin in breast cancer are related to inhibiting invasion and downregulating the phosphatase and tensin homolog (PTEN)/Akt pathway via the promotion of RhoB, both *in vitro* and *in vivo* [100].

In tumorigenesis, the restructuring of the actin cytoskeleton has been one of the key pathways associated with cell migration regulation [101]. Many factors, including small GTPases like RhoA, facilitate actin reorganization and cellular migration [102]. Throughout these scenarios, simvastatin inhibits stemness-related gene expression and metastatic invasions through the degradation of the cytoskeleton in human cancer cells [103]. Atorvastatin has been shown to enhance oxidative stress and inhibit the cell proliferation of oral squamous carcinoma *in vitro* [104]. The majority of reports regarding simvastatin therapy have shown that survivin is reduced significantly and is implicated in tumorigenesis [105]. Invasion assays have revealed that simvastatin (0–50 μM) treatment inhibits the invasiveness of salivary adenoid cystic carcinoma (SACC‐83) cells dose‐dependently, and downregulates survivin expression [106]. In the next

section, we discuss the anticancer activity of statins, with a focus on their possible advantages in the treatment of GBM.

## 3. GBM and statins

GBM shows fast development, high invasiveness, and apoptosis resistance [107]. As a drug repositioning strategy, alternative treatment approaches should aim to inhibit proliferation and induce cell apoptosis [108, 109]. The inhibition of HMGCR leads to suppression of tumor growth and induction of apoptosis in multiple tumoral cell lines; however, the precise molecular pathways of statins, as potential HMGCR inhibitors, are not well known in GBM [110]. In the following subsections, we have summarized the potential mechanisms and antitumor effects of statins in GBM from both preclinical and clinical studies.

### 3.1. Insights from preclinical studies

As discussed earlier, the mevalonate pathway is responsible for cholesterol biosynthesis and the formation of the intermediate metabolites GGPP and FPP used in the prenylation of proteins [27]. Notably, mevalonate and GGPP pretreatment cause significant inhibition of statin-induced apoptosis [18], and simvastatin induces cell death via the intrinsic apoptotic pathway in a wide range of human tumor cell lines, including astrocytoma, neuroblastoma, and GBM [111]. For instance, atorvastatin improves the efficacy of TMZ in GBM by suppressing Ras-signaling in a prenylation-dependent way [112, 113]. Herein, cholesterol-lowering statins tend to enhance the clinical results of several malignancies by suppressing the mevalonate pathway that promotes apoptosis inhibition and cellular proliferation [114].

Laboratory evidence indicates that statins are emerging as possible future antitumor agents with pro-apoptotic, anti-proliferative, anti-invasive, radiosensitive, and radioprotective activities in

GBM [115-117]. However, these preclinical studies have included high concentrations of statins in comparison with the clinical plasma concentration utilized as a lipid-lowering agent [118, 119]. For instance, Weiss *et al.* have shown that statins have proangiogenic impacts at low therapeutic doses (nanomolar) but antiangiogenic effects at high doses (micromolar) that are reversed by GGPP [118]. One of the fundamental problems in clinical GBM therapy is the development of TMZ resistance in GBM after continuous treatment with TMZ [108]. Recently, statin therapy has demonstrated an improved anti-GBM effect of TMZ *in vitro*; however, the study used a high-dose of statins compared to clinically therapeutic concentrations [120]; therefore, the antitumor activities of statins against GBM are different from the anti-lipid effects and may rely on its concentration for efficacy [113, 121].

Recently, it has been found that the mevalonate pathway (as a metabolic regulator of autophagy) and basal autophagic flux are inherently connected to cell growth [122]. Autophagy is a catabolic process that recycles degraded proteins and organelles in metabolic stress, such as nutrient deprivation and chemotherapy treatments [123]. In GBM, it has been shown that autophagy inhibition, either at onset or in the late autolysosome fusion process, may improve apoptosis induced by TMZ, indicating that autophagy suppression would strengthen the efficacy of chemotherapy based on TMZ [124]. One problem is the fact that autophagy triggers cell apoptosis and mortality in some other circumstances so that the specific role of autophagy modulators in apoptosis-sensitive tumors needs to be studied [125].

Numerous *in vitro* findings have shown that pitavastatin, cerivastatin, and fluvastatin were the most potent autophagy-inducing agents in human cancer cells, including stem cell-like primary GBM cell lines. In line with this, the knockdown of GGPP synthetase-1 also induces robust cell autophagy and cell death *in vitro* and reduces GBM tumor growth *in vivo*. Simulated models have

shown that statins cause autophagy in U251 cells and have been related to an increase in Beclin1, ATGB13, and autophagosomes [126], indicating that statins may trigger cell death by autophagy.

Pharmacologically, lovastatin potentially triggers autophagy induction by Akt/mTOR signaling cascade inhibition. Also, by suppressing lysosomal associated membrane protein-2 and dynein, lovastatin may affect the autophagosome-lysosome fusion machinery. These outcomes indicate that the efficacy of TMZ chemotherapy in GBM cells could be significantly improved by lovastatin. The mechanism can be related to impaired autophagic flux, enhancing apoptosis of the malignant cells; therefore, combining TMZ and lovastatin could be a promising GBM therapy intervention through autophagy mechanism [127]. The combinational strategy between statins and TMZ has shown promise for the treatment of GBM. Simvastatin, a blood-brain barrier permeable statin, also inhibits the autophagy flux induced by TMZ by blocking autophagolysosomal formation [125, 128]. Inconsistent with the previous studies, Oliveira *et al.* have shown that atorvastatin and TMZ treatment increase acidic vesicular organelle (AVO) presence in A172 GBM cells, an indicative of autophagy [129]. Simvastatin (0–50 μM) also was shown to cause the appearance of autophagolysosomal-like intracytoplasmic acidic vesicles in U251 and C6 GBM cells. Mechanistically, the upregulation of the autophagosome-associated LC3-II, pro-autophagic beclin-1, and the downregulation of the selective autophagic target p62 confirm the simvastatin-induced autophagy *in vitro*. Interestingly, simvastatin induces the activation of AMP-activated protein kinase (AMPK) and inhibits the mTOR, a central negative regulator for autophagy and Akt activation. With these notable findings, Misirkic *et al.* have suggested that inhibition of AMPK-dependent autophagic response might sensitize GBM cells to statin-induced apoptotic cell death [130].

Statins have also been shown to suppress tumor growth and boost apoptosis in GBM [131]. In this regard, it has been reported that lovastatin could sensitize GBM cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis [132]. In GBM cell lines, as well as tumor-bearing mice, lovastatin significantly increases the expression of DR5, inducing the extrinsic apoptosis pathway [133]. Much further along, lovastatin treatment could mitigate the ERK/MAPK and nuclear factor-kappa B (NF-κB) pathways. Still, it does activate the Janus kinase (JNK) path, indicating that lovastatin sensitizes TRAIL-induced apoptosis by the DR5 up-regulation through inhibiting NF-κB, but also directly triggers the apoptosis via MAPK pathway dysregulation [134]. Based on previous studies, lovastatin has been reported to induce GBM cell death dose-dependently and to improve short- and long-term cytotoxicity of TMZ. Also, concurrent lovastatin with TMZ behaves synergistically in cell apoptosis, indicating the potential role of lovastatin as a synthetic booster in GBM treatment [127]. Regarding the intrinsic pathway of apoptosis, atorvastatin (10 μM) induces apoptosis of GBM spheroids through caspase-8/-3 activation, downregulating Bcl-2, TRAF3IP2, and interleukin (IL)-17RA expression [135-137].

Human tumors are commonly described by a significant reduction of histone acetylation that is regarded as a global epigenetic indicator for malignancy. Histone deacetylase (HDAC) upregulation is observed in a wide variety of human cancer cells, like colon, stomach, renal, breast, and brain [138, 139]. Recent studies have revealed that statins inhibit HDAC activity and, consequently, increase p21 expression in various cancer cells, including GBM. Interestingly, it has been shown that fluvastatin in combination with valproate sodium, a well-known HDAC inhibitor, effectively induces H2A histone family member X (γ-H2AX) and apoptosis in GBM8401 cells followed by enhanced histone H3 and H4 acetylation. This combination also leads to p21 upregulation, which plays a significant part in the cell cycle and apoptosis [140].

Molecularly, in GBM, there are several main possible targets for modified anti-angiogenesis, anti-invasiveness, and apoptosis-inducing effects, including PI3K/Akt, MMPs activity, and the TGF-β signaling pathway [141, 142]. The PI3K/Akt signaling pathway is involved in the regulation of multiple cellular physiological processes by activating downstream corresponding effector molecules, which serve an essential role in the cell cycle, tumor growth, apoptosis, invasion, migration, angiogenesis, cell proliferation, and chemoresistance [143]. A common phenomenon is over-activation of the pathway that is present in human malignancies and has been implicated in cancer progression; therefore, one of the most critical approaches to the treatment of GBM is rational drug design using molecular targets in the PI3K/Akt signaling pathway [144].

Some studies have found that inhibition of the HMGCR pathway mediates the role of statins to cause apoptosis via downregulation of the PI3K/Akt pathway, the activation of JNK1/2, an increase in the expression of Bax and Bim, and caspases activation on GBM [145, 146]. In line with this, the cytotoxicity of statins (mevastatin, fluvastatin, or simvastatin, 1-20 μM) toward the C6 GBM cells have been evaluated by Yanae *et al*. Statins have been shown to suppress cell proliferation and induce apoptosis in these cells through caspase-3 activation and ERK1/2/Akt inhibition [18]. Furthermore, modulation of lipid rafts, Fas translocation, downregulation of PI3K/Akt, and caspase-3 activation is involved in the antitumor effect of simvastatin in U251 and U87 MG GBM cells, as evaluated by Wu *et al.* [147].

The invasion of cancer is a fundamental determinant of cancer malignancy assessment [148]. Numerous studies have indicated that microglia activated by GBM cells can promote cell proliferation, migration, and invasion through MMPs expression. Besides, the forced expression of HMGCR promotes the growth and migration of GBM cells while the inhibition of HMGCR expression inhibits the growth, migration, and metastasis of GBM cells [149]. Gliemroth *et al.*

have shown that simvastatin (0.2–30 μM) inhibits tumor cell growth and migration, but the invasiveness of the remaining U87 MG cells seems to be unaffected [150]. Some studies have shown that atorvastatin can decrease MMP-2/-14/-9 expression levels and significantly reduce the invasion of cancer cells via the RhoA-JNK-c-Jun-MMP-2 signaling pathway by suppressing MMP-2 activity [151, 152]. Statins have been shown to decrease MMP-2 expression significantly, which can mitigate GBM cell invasion. For instance, simvastatin and atorvastatin have been shown to inhibit proliferation and migration of U251, U87 MG, and U87 MG spheroid cells [135, 147]. The antiproliferative and anti-invasiveness effects of fluvastatin appear to be linked with p-JNK1/2 upregulation, p-ERK1/2 expression reduction, and a decrease in the MMP-9 activity in C6 rat malignant GBM cells [153]. Sundararaj *et al.* have shown that simvastatin can repress lipopolysaccharide-induced expression of MMP-1 in U937 cells by targeting ERK activation through protein isoprenylation [154]. GBM also manipulates membrane type (MT)-1-MMP expression in tumor-related microglial cells, promoting the expansion and invasion of GBM via the toll-like receptor (TLR) signaling pathway. In a study by Yongjun *et al.*, it has been found that atorvastatin suppresses GBM invasion and migration by reducing microglial MT1-MMP expression, which leads to suppression of MMP-2 activity [155].

RhoA activation results in integrin clustering, facilitating focal adhesion (FA) kinase activation (FAK) by tyrosine phosphorylation 397 [156]. FAK signaling cascades govern the invasion and metastasis of cancer cells by regulating MMP expression and the assembly of the focal complex at the leading edge and the disassembly of the FA at the trailing edge of the cell [157, 158]. In a study done on GBM cells, cerivastatin was used to inactivate FAK by disrupting the cytoskeleton, leading to the inhibition of migration [159], suggesting that cerivastatin may be beneficial for combination therapy with conventional anticancer drugs by inhibiting the invasion of GBM.

In the inflammatory pathway of TGF-β, cerivastatin drives the expression of p21 and other tumor suppressors. It acts to curb the cell cycle and stimulates EMT, fostering invasion, metastasis, and possibly treatment resistance [160]. Recently, a probable link has been noted between the statins and TGF-β in various cancer cells. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins through mevalonate reduces the expression of TGF-β as an angiogenic factor [161]. Xiao *et al.* have found that simvastatin (0–50 μM) affects human GBM cells (U87 MG, U251 MG, and T98G cells) through TGF-β inhibition, inducing angiogenesis inhibition. Other experiments in this study have shown that simvastatin reduces GBM migration and invasion, and induces apoptosis and autophagy, both *in vitro* and *in vivo* [162]. These studies have confirmed that statins are of critical significance for GBM patients undergoing angiogenesis target therapy. For instance, atorvastatin has a potent anti-angiogenic effect against GBM spheroids via downregulating the expression of vascular endothelial growth factor (VEGF) and CD31, as demonstrated in a three-dimensional *in vitro* model [136]. Also, it has been shown that low-dose simvastatin increases necrosis and apoptosis compared to both control and high-dose simvastatin groups, *in vivo*. High-dose simvastatin increases vessel caliber by reducing pericytic cells along the tumor vessel wall compared to both control and low-dose simvastatin groups, demonstrating a dual role for simvastatin in GBM [163]. In the framework of stimulation of the Ras–Raf–MEK–ERK pathway, prenylation by FPP and GGPP is required for the oncogenic activity of Ras and Rho proteins [164]. Another point from the studies on HMGCR inhibitors is that statins reduce the levels of FPP and GGPP and decrease ERK signaling, which mitigate cancer cell migration and proliferation [165]. It has been stated that lovastatin affects H-Ras and Rac1 post-translation modifications and influences the mevalonate and Ras–Raf–MEK–ERK regulation in U343 and U87 MG GBM cells

[164]. Even so, it is necessary for these results to be verified by sufficiently scaled randomized controlled studies and meta-analysis of available data.

## 4. Observations from clinical studies

An increasing body of preclinical data indicates that statins may have powerful antitumor effects, but their interaction with standard therapy and clinical results in cancer patients is less clear [166]. Recently, in a study involving 303 patients with advanced pancreas adenocarcinoma, Iarrobino *et al.* have demonstrated the impact of statin use on outcomes, and it was found that statin (simvastatin and atorvastatin) usage is correlated with increased OS in affected patients. Statin usage has also been reported to have been associated with significantly reduced all-cause mortality, mainly by lowering the risk of distant metastases before or during diagnosis [167]. Furthermore, in patients undergoing radiation therapy, surgery, and chemotherapy, statin treatment is correlated with a 2-year increase in the OS of patients, suggesting that statins may work to improve outcomes for advanced-stage pancreatic cancer interventions [168]. In another study, Lin *et al.* have shown the efficacy of statin use in a large cohort of patients with stage IV non-small-cell lung cancer. In the statin group, median survival was seven months compared to four months in non-statin patients. Also, statin use was associated with improvement in OS and lung cancer-specific survival [169]. Conversely, Omori *et al.* have found that OS was not improved; however, they did show that statins improve OS in patients previously treated with nivolumab for advanced non-small cell lung cancer [170].

Although some findings have shown that statin use has a possible chemical-preventative impact on the treatment of cancer, the effects of statins on the prognosis of GBM have yet to be examined. Gaist *et al.* and Chen *et al.* have shown that long-term prediagnostic statin use may improve the

survival of GBM patients and reduce the risk of brain cancer [21, 171]. Also, for patients with GBM who were taking a statin for >1 year, a significant enhancement in OS was observed. Although based on limited statistical precision, the probable chemoprevention impact was restricted to lipophilic statin consumers. This may be explained by the biochemical properties of lipophilic statins, with their higher capacity than hydrophilic statins, to cross the blood-brain barrier [172]. Conversely, the use of perioperative statins is not associated with improvement in progression-free survival (PFS), and mortality was similar between both groups of GBM patients [114]. In line with this finding, a secondary analysis of two large GBM trials was unable to detect evidence for an association of the use of statins with outcomes in patients with newly diagnosed GBM [173]. A study by Seliger *et al.* has shown that the use of statins was unrelated to OS or PFS of GBM patients [174], and the use of statins was not associated with the risk of GBM [175]. Furthermore, Cote *et al.* have found a borderline increased risk of GBM with statin use [176]. A phase II study of atorvastatin in combination with radiotherapy and TMZ in patients with GBM is ongoing (NCT02029573) [177].

Lovastatin with and without radiation therapy has been well-tolerated in phase I/II trial of 18 patients with malignant GBM, and a marginal effect on tumor development has been reported thus far [178]. A case-control study has shown the risk of GBM among statin users, stating that simvastatin therapy for more than six months was inversely associated with glioma risk [179]. In Table 4, we summarized recent combinational therapies-based statins affecting GBM in both preclinical and clinical studies.

## Concluding remarks

Statins have non-lipid-related effects, widely recognized as pleiotropic drugs, exert anti-inflammatory, immunomodulatory, and antioxidant activities [180-184]. During the past few years, a plethora of evidence has shown that statins activate apoptosis and inhibit cell growth of various types of malignant cells *in vitro* and *in vivo*. Statins display such effects in humans, which increase the prospects for their potential future effectiveness in preventing and/or treating some malignancies. These outcomes are gaining interest in the treatment of cancer; therefore, preclinical findings from antitumor activities of statins require special consideration as a possible therapeutic strategy.

Standard anticancer treatment for GBM, one of the deadliest and most invasive brain cancers, remains unreliable. The impact of statins on GBM, a group of mainly unknown etiological brain tumors, is a field of inquiry that needs special attention [185]. In this review, we highlighted a variety of new hypotheses regarding the potential re-targeting of statins for GBM patients. In this regard, we showed that targeting the mevalonate pathway, and consequently GTPases (Rho, Rac1, Ras), could be a potential target for treating GBM through autophagy, apoptosis, and metastasis modulation. Statins could help to improve this situation by regulating several signaling pathways, including: (1) potentiating the anti-GBM activity of chemotherapeutic drugs, (2) activating the intrinsic and extrinsic apoptosis pathways, (3) autophagy modulation, (4) EMT outgrowth and metastatic behavior regulation, (5) the destruction of angiogenic blood vessels, and (6) TGF-β modification (see Fig. 3). In light of the generally positive results from statin use in GBM in preclinical and small-scale clinical studies, larger-scale prospective clinical findings are much needed. The lack of financial benefit from performing major randomized controlled trials (RCTs) may be a significant reason for the current lack of studies with this focus. It is our intent that this review will act as a catalyst for others to concentrate on this emerging and essential issue.

## Funding

None.

## Conflicts of Interest

The authors declare no conflict of interest.

**Table 1.** Apoptosis-inducing impacts of statins in various cancer cells.

| Statin (s) | Type of study | Dose of administration | Primary mechanism (s) | Reference |
|---|---|---|---|---|
| Simvastatin | *In vitro* (HT-29 cells) | 2.5–20 μM | 1- Apoptosis-inducing effects via caspase-3 activation<br>2- Inhibiting IGF‐1‐induced ERK and Akt expression via the downregulation of IGF‐1R expression and pro-apoptotic ERK activation | [186] |
| Simvastatin-loaded emulsomes | *In vitro* (MCF-7 cells) | 0.1, 1, 10, 100, 1000 μM | 1- An increase in early and late apoptosis<br>2- An increase in caspase-3 and Bax | [187] |
| Atorvastatin, fluvastatin and simvastatin | *In vitro* (A20 and EL4 cells) | 0–5 μM | 1- DNA fragmentation<br>2- Activation of pro-apoptotic members, like PARP, caspase-3, and Bax<br>3- Suppressing the activation of Bcl-2<br>4- Promoting intracellular ROS generation<br>5- Regulating Akt, ERK and p38 MAPK signals via inhibition of the mevalonate pathway | [188] |
| Atorvastatin, pravastatin, lovastatin, and simvastatin | *In vitro* (rat vascular smooth muscle cells) | 0–100 μM | Inducing apoptosis | [189] |
| Simvastatin | *In vitro* (human leiomyoma cells) | 0–10 μM | 1- An increased expression of Bim | [190] |
| | | | 2- Increased $Bim_{EL}$ activity and mitochondrial leakage of apoptosis-initiating proteins, such as cytochrome c<br>3- Decreased ERK activation<br>4- Calcium-dependent apoptosis | |
| Simvastatin and fluvastatin | *In vitro* (PC3 cells) | 0–20 μM | 1- A decrease in cell proliferation<br>2- Inducing cell apoptosis via downregulation of AKT/FOXO1 phosphorylation | [191] |
| Simvastatin | *In vitro* (HCT116 cells)<br>*In vivo* (tumor xenograft model) | 0–50 μM | 1- Suppressing survivin expression through activating p38 MAPK and p53<br>2- Inducing cell apoptosis through activating p38 MAPK<br>3- Suppressing survivin expression and tumor growth in the xenograft tumor model | [192] |
| Lovastatin and atorvastatin | *In vitro* (Hey 1B and Ovcar-3 cells) | 0–20 μM | 1- Activation of JNK<br>2- Enhancement of Bim expression<br>3- Suppressed anchorage-independent growth | [193] |
| Simvastatin | *In vitro* (Daoy, D283, and D341 cell lines) | 0.5–20 μM | 1- Inducing caspase-dependent apoptosis via the mevalonate pathway | [194] |
| Atorvastatin, rosuvastatin, pravastatin, and simvastatin | *In vitro* (MCF-7, MDA-MB-231, SF-295, DU-145, and DU-145 cells) | 0–60 μM | 1- Suppressing micrometastasis outgrowth<br>2- Inhibition of PI3K signaling through Akt<br>3- A decrease in EGF-mediated phosphorylation of Akt | [11] |
| Fluvastatin and pravastatin | *In vitro* (Huh-7 and HepG2) | Fluvastatin: 0–50 μM<br>Pravastatin: 0–500 μM | 1- Inducing apoptosis<br>2- A breakdown of the MMP<br>3- Caspase activation and nuclear degradation | [70] |
| Simvastatin | *In vitro* (MCF-7, T47D, MDA-MB-231, and BT-549)<br>*Clinical study* | 0–50 μM | 1- Inhibiting MAPK/ERK pathway by dephosphorylating sequential cascades, like ERK1/2 and MEK1/2<br>2- Deactivating PI3K/Akt/mTOR | [71] |

| | | | | |
|---|---|---|---|---|
| Fluvastatin | *In vitro (PCa cells) Clinical study (NCT01992042)* | In vitro: 0.0–1.1 μM Clinical trial: 80 mg for 4–12 weeks | 1- Inducing cell death, dose- and time- dependently<br>2- An increase in caspase-3 activity | [195] |
| Simvastatin, pravastatin, mevastatin and lovastatin | *In vitro* (Human embryonic stem cells (hESC) (HES3), karyotypically abnormal hESC (BG0IV), embryonal carcinoma (NTERA-2), ovarian (TOV-112D) and colorectal cancer (HT-29) cells) | 0–20 μM | 1- Inhibiting cell proliferation via an increase in the activity of apoptotic genes<br>2- Inhibition of stemness-related genes on chromosomes 12 and 17 | [196] |
| Atorvastatin | *In vitro* (MCF-7 cells) | 0–80 μM | Induction of both apoptosis and autophagy | [197] |
| Simvastatin | *In vitro* (UMR-106) | 0–10 μM | Inducing apoptosis | [198] |
| Simvastatin and atorvastatin | *In vitro* (LU1205, WM9, WM35, WM164, WM793, WM852 [58], FEMX, LOX, HHMSX A375 and HTB-11 cells) | 20–40 μM | 1- Increased TRAIL-induced apoptosis<br>2- Suppression of the NF-κB and STAT3-transcriptional targets (including COX-2)<br>3- Downregulation of cFLIP-L protein level | [199] |
| Simvastatin, lovastatin, and pravastatin | *In vitro* (OE33 and BIC-1 EAC cells) | 0–100 μM | 1- Inhibition of Ras farnesylation<br>2- Inhibition of the ERK and Akt signaling pathways | [200] |
| Simvastatin | *In vitro* (SNU-245) | 0–500 μM | 1- G1 phase cell cycle arrest<br>2- Inducing apoptosis via caspase-3 activation,<br>3- Downregulation of Bcl-2 expression and enhancement of Bax expression<br>4- Suppressing IGF-1R expression and IGF-1-induced ERK/Akt activation | [201] |
| Simvastatin | *In vitro* (MCF-7 and MDA-MB 231 cells) | 0–200 μM | Inducing apoptosis via involvement of JNK independent of their ER or p53 expression status | [56] |
| Simvastatin | Clinical study | 0–120 μM | Apoptosis initiating by the mitochondrial caspase-9, which indirectly leads to activation of caspase-3/-8 | [202] |
| Simvastatin | *In vitro* (AXT, Saos2, and U2OS cells)<br>*In vivo* | 0–5 μM | 1- Inducing apoptosis via activation of AMPK and p38 MAPK<br>2- Inhibiting migration | [203] |
| Simvastatin | *In vitro* (MNNG/HOS osteosarcoma cells) | 0–64 μM | Apoptosis induction through inactivation of PI3K/Akt signaling pathway | [204] |
| Atorvastatin | *In vitro* (HCC cells) | 0–40 μM | 1- Inducing cell growth inhibition and G0/G1 phase cell cycle arrest, leading to senescence<br>2- A decrease in tumor growth in mouse xenograft models<br>3- A reduction in the IL-6, p-STAT3, and hTERT levels<br>4- An increase in β-gal expression in tumor sections | [205] |
| Lovastatin | *In vitro* (Fadu hypopharyngeal carcinoma cells) | 0–50 μM | cell death via AMPK-p63-survivin signaling cascade | [206] |
| Lovastatin | *In vitro* (MCF-7 cancer cells) | 0–50 μM | 1- The p53 activation<br>2- Cell death via LKB1-AMPK-p38MAPK-p53-survivin signaling cascade | [207] |

| | | | | |
|---|---|---|---|---|
| Atorvastatin | *In vitro* (K562 and HL60 cells) | 0–80 μM | 1- Inducing apoptosis via an increase of ROS and Bax/Bcl-2 ratio, loss of MMP<br>2- Activation of Bax/Caspase-9/Caspase-3/PARP pathway | [10] |
| Simvastatin | *In vitro* (MDA-MB-231 cells) | 0–5 μM | Cell death through oxidative stress upregulating miR-140-5p | [208] |
| Pitavastatin | *In vitro* (SCC15 and SCC4 cells) | 0–0.5 μM | 1- Suppressing cell proliferation<br>2- Inducing intrinsic apoptosis in a FOXO3a-dependent manner<br>3- Inducing the nuclear translocation of FOXO3a via dual regulation of two upstream kinases, AMPK and Akt, resulting in the up-regulation of PUMA | [209] |
| Simvastatin | *In vitro* (ER-positive (MCF-7, T47D) and ER-negative (MDA-MB-231, BT-549) breast cancer cells) | 0–50 μM | 1- Inducing apoptosis and inhibiting proliferation<br>2- Suppressing PI3K/Akt/mTOR pathway via PTEN upregulation and dephosphorylating downstream cascades including Akt, mTOR, p70S6K, S6RP, and 4E-BP1<br>3- Inhibiting MAPK/ERK pathway by dephosphorylating sequential cascades such as c-Raf, MEK1/2, and ERK1/2 | [71] |
| Encapsulation of Lovastatin in Zein Nanoparticles | *In vitro* (HepG2 cells) | 0–30 μM | 1- Induction of apoptosis via caspase-3 activation<br>2- Inducing a significant cell accumulation in the G2/M and pre-G phases | [210] |
| Simvastatin | *In vitro* (LipPD1 cells) | 0–10 μM | 1- Inducing PTEN transcriptional upregulation by increasing PPAR-γ expression<br>2- Reducing cell viability and inducing apoptosis | [211] |
| | | | 3- An increase in the mRNA expression of cellular PTEN<br>4- Inhibition of the phosphorylation of Akt and downstream targets of mTOR and 4E- BP- 1 | |
| Atorvastatin | *In vitro* (HepG2 hepatocellular carcinoma cells) | 0–30 μM | 1- Increasing activities of caspases-9, -3 and -7<br>2- An increase in protein expression of pGSK3, p53, and Mdm2<br>3- A decrease in protein expression of PI3K, p-AKT, and AKT<br>4- Modulating expression of miR-145 | [212] |
| Simvastatin-alpha lipoic acid nanoparticles | *In vitro* (breast carcinoma cell lines MCF-7) | 0–50 μM | 1- DNA fragmentation<br>2- Inducing cell death | [213] |

**Table 2.** The effects of statins on the cell cycle of multiple cancerous cells.

| Statin (s) | Cell line | Dose of administration | Main finding (s) | Reference |
|---|---|---|---|---|
| Pravastatin and fluvastatin | Hepatocellular carcinoma cells | Fluvastatin: 0–50 μM<br>Pravastatin: 0–500 μM | G1/S cell cycle arrest | [70] |
| Simvastatin | Hepatocellular carcinoma cells | 0–20 μM | G0/G1 arrest by inducing p21 and p27 accumulation through inhibition of STAT3/SKP2 axis and activation of AMPK | [214] |
| Fluvastatin and simvastatin | Human acute promyelocytic leukemia cells | 0–100 μM | 1- Cell cycle arrest at G1 phase via p27 upregulation<br>2- Inhibition of Ras/ERK and Ras/mTOR pathways | [58] |
| Fluvastatin and pitavastatin | Vascular smooth muscle cells | 0–10 μM | Suppressing the protein expressions of cyclin D1 and CDK4, but inducing p27 | [215] |
| Fluvastatin and Simvastatin | Jurkat and CCRF-CEM cells | 0–200 μM | 1- Arresting in G1 phase through inhibition of the Akt pathway<br>2- Upregulation in p21 and p27 protein expression<br>3- Downregulating in cyclin D1 | [216] |
| Simvastatin | HC15 cells | 0–25 μM | Inducing the arrest of the cell cycle in the G1/S phase through downregulation of cyclin A | [217] |
| Simvastatin | MCF-7 cells | 0–1000 μM | Inducing cell cycle arrest and apoptosis | [218] |
| Pravastatin | Multiple myeloma cells | 0–0.9 μM | Arrest in the G0/G1 phase of the cell cycle | [219] |
| Atorvastatin calcium | Vascular smooth muscle cells | 0–10 μM | G0/G1 cell cycle arrest and suppression of the PDGFRβ-Akt signaling cascade | [220] |
| Simvastatin | MNNG/HOS osteosarcoma cells | 0–64 μM | G0/G1 phase arrest via down-regulation of cyclin D1, CDK2, CDK4 as well as up-regulation of p21 and p27 | [204] |
| Simvastatin | THP1 cells | 0–100 μM | Cell cycle arrest | [221] |
| Lovastatin | Sphere-forming cells derived from the 5-8F and 6-10B NPC cells | 0–10 μM | Cell cycle arrest at the G2/M phase | [222] |
| Lovastatin | Fadu hypopharyngeal carcinoma cells | 0–50 μM | Sub-G1 peak apoptosis | [206] |
| Simvastatin | T47D breast cells | 0–50 μM | Decrease in the cyclin D1 expression, inducing apoptosis | [223] |
| Pitavastatin | Huh-7 and SMMC7721 cancer cells | 0–20 μM | Inhibiting growth and colony formation<br>Inducing arrest at the G1 phase<br>Promoting caspase-9/-3 cleavage | [224] |

**Table 3.** Combinational strategies with statins in various cancer models.

| Combination regimens | Type of study | Main effect (s) | Reference |
|---|---|---|---|
| Pravastatin + sorafenib | *Phase III, multicenter study* | Did not improve OS in the affected population | [225] |
| Pitavastatin and fluvastatin + erlotinib | *In vitro* | 1- Synergistically enhanced cytotoxicity compared to pitavastatin monotherapy<br>2- Induction of alternative regulated cell death pathways | [226] |
| Statins + metformin | *Clinical study* | No beneficial effect was observed for dual users | [31] |
| Low-dose mixed micellar simvastatin + alendronate sodium | *In vitro* | 1- Inhibiting the cell growth | [227] |
| | | 2- Inhibiting the cell multiplication in the S phase and resulted in high % of late apoptotic and necrotic cells | |
| Simvastatin/fluvastatin + everolimus | *In vitro*<br>*In vivo*<br>*Clinical study* | 1- An improve in PFS of patients treated with everolimus<br>2- Showing the combined effect *in vitro* and *in vivo* assays<br>3- Impeding the prenylation of KRAS or Rac1 to sensitize cells to mTOR inhibition with RB protein activation<br>4- Enhancing the efficacy of an mTOR inhibitor in vivo | [228] |
| Mevastatin + LBH589 | *In vitro*<br>*In vivo* | 1- Cell cycle arrest in the G2/M phase and induced corresponding expression changes of proteins regulating the cell cycle<br>2- An increase in apoptosis both *in vitro* and *in vivo*, and reduced tumor volumes in xenografted mice | [229] |
| Simvastatin + celecoxib | *In vitro* | A significant reduction in tumor cell viability, proliferation, and secretion of IL-6 and IL-8 | [230] |
| Pitavastatin + dacarbazine | *In vitro* | 1- G1 cell cycle arrest<br>2- Activating apoptosis via an increase in the levels of active caspase-3 and cleaved PARP and release of cytochrome c<br>3- Autophagy induction | [231] |
| Simvastatin + doxorubicin | *In vitro* | 1- A decrease in the colony- forming ability of cells<br>2- An increase in ROS levels<br>3- A drop in expression of the cell cycle regulatory protein, including CDK2, CDK4, and CDK6<br>4- Inducing expression of the cyclin- dependent kinase inhibitor p21, increased cytochrome c and caspase-3 expression and reduced cyclin D1 expression | [232] |
| Fluvastatin + ALA and EA in an NLC[1] formula | *In vitro* | A significant increase in pre-G1 phase, inducing cell death | [233] |
| Simvastatin + herceptin-conjugated liposomes co-loaded with doxorubicin | *In vitro*<br>*In vivo* | 1- A potent proliferation inhibition of cancer cells<br>2- A synergistic anti-angiogenesis effects | [234] |
| Pitavastatin + doxorubicin | *In vitro* | 1- Increasing levels of p53 and the cell cycle regulator p21<br>2- Inducing apoptosis via activation of caspase-9, caspase-7 and the reduction of Bcl-2 level | [235] |
| Lovastatin + cisplatin | *In vitro and in vivo* | 1- Sensitizing the cells to cisplatin-induced apoptosis and suppressed the activation of CHK1, CHK2, and H2AX during DNA damage response<br>2- Promoting the therapeutic efficacy of cisplatin, and significantly prolonged the survival times of tumor-bearing mice | [236] |
| Atorvastatin + nobiletin | *In vitro*<br>*In vivo* | 1- Synergistically inducing extensive cell cycle arrest and apoptosis<br>2- A decrease in colonic tumor incidence and multiplicity | [237] |
| Atorvastatin + cyanidin-3-glucoside | *In vitro* | 1- Exhibiting a synergistic effect in inhibiting proliferation and migration by enhancing cell cycle arrest<br>2- A decrease in MAPK activity by attenuating the expression of p-p38, p-ERK1/2, and p-JNK<br>3- Modulating the PI3K/Akt pathway and upregulating p21Cip1 | [238] |

| | | | |
|---|---|---|---|
| Troglitazone + lovastatin | *In vitro and in vivo* | 1- Tumor regression in a mouse xenograft model<br>2- Cell cycle arrest at the G0/G1 phase, as evidenced by the induction of cyclin-dependent kinase inhibitors, p21cip and p27kip, and the reduction of hyperphosphorylated retinoblastoma protein (pp-Rb)-E2F1 signaling | [239] |
| Simvastatin + metformin | *In vitro* | 1- Apoptosis induction<br>2- The mTOR pathway inhibition | [240] |
| Simvastatin + irinotecan | *In vitro* | 1- A significant inhibition of cell growth<br>2- A remarkable increase in the percentage of apoptotic cells and those accumulated at the G0/G1 phase<br>3- Caspase-independent apoptosis | [241] |
| | | 4- Upregulation of GRP-78 level and downregulation of Mcl-1 levels in a time-dependent manner | |
| Simvastatin + bergamottin | *In vitro* | 1- Apoptosis induction by TNF<br>2- Down-regulation of various gene products that mediate cell proliferation (cyclin D1), cell survival (cIAP-1, Bcl-2, Bcl-xL, and Survivin), invasion (MMP-9) and angiogenesis (VEGF), regulated by NF-κB<br>3- Producing TNF-induced cell-cycle arrest in S-phase<br>4- inhibiting TNF-induced NF-κB activation, IκBα degradation and p65 translocation to the nucleus | [242] |
| Simvastatin + paclitaxel lipid nano emulsions | *In vivo* | 1- Tumor-growth inhibition<br>2- An increase in the expression of p21<br>3- A decrease in the expression of cyclin D1 | [243] |
| Simvastatin+ pentoxifylline | *In vitro* | 1- An increase in ERK1/2 and Akt activation<br>2- Suppression of the NF-κB pathway<br>3- Arrest at the G0/G1 phase<br>4- Attenuating colony-forming ability<br>5- Induction of autophagy | [244] |
| Simvastatin + tamoxifen | *In vitro*<br>*In vivo* | 1- Inhibiting the increase in oxidative stress markers, LDH, and NF-κB<br>2- A decrease in the total apoptotic ratio, caspase-3 activity, and glucose uptake, without a significant change in Bax/Bcl-2 ratio<br>3- Exerting antagonistic effects | [245] |
| Simvastatin + IR | *In vitro* | 1- A decrease in G2/M arrest and DNA damage<br>2- MDM2 suppression<br>3- Accumulation of the FOXO3a, E-cadherin, and p21 tumor suppressor proteins, which are downstream factors of MDM2 | [246] |
| Atorvastatin + IR | *In vitro* | Enhancing radiosensitivity HIF-1α inhibition | [247] |
| Atorvastatin + metformin | *In vitro* | 1- Cell growth inhibition and apoptosis induction<br>2- Inhibiting cell migration and the formation of tumor spheres<br>3- Potent inhibitory effect on NF-κB activity and caused substantial decreases in the expression of its downstream antiapoptotic gene Survivin<br>4- Reduction in the levels of phospho-Akt and phosphor-ERK1/2 | [248] |
| Atorvastatin + caffeine | *In vitro* | 1- Cell growth inhibition and apoptosis induction<br>2- Inhibiting invasion, migration, and the formation of tumor spheres<br>3- Downregulating phospho-ERK1/2, phospho-Akt, Bcl-2 and Survivin protein levels | [249] |
| Simvastatin + receptor-interacting protein 140 | *In vitro* | Inhibition of cell proliferation and survival, through the Wnt/β- catenin signaling pathway | [250] |
| Simvastatin + oxicam derivates | *In vitro* | 1- Inducing apoptosis through a caspase-3-dependent pathway upregulated Bax expression, and down-regulated Bcl-2 expression reduced expression and activity of COX2 | [251] |
| Simvastatin + tamoxifen | *In vitro and in vivo* | 1- An increase in the apoptotic and necrotic cell death<br>2- A decrease in VEGF and MMP-2/-9 | [252] |

| | | | |
|---|---|---|---|
| Fluvastatin + vorinostat | *In vitro and in vivo* | 1- A robust apoptosis induction and inhibiting cancer growth<br>2- Enhancing vorinostat- induced histone acetylation<br>3- Inducing ER stress<br>4- Inhibiting the mTOR pathway and AMPK activation | [253] |
| Pitavastatin + gemcitabine | *In vitro and in vivo* | 1- Synergistically suppression of the cell proliferation through sub-G1 and S-phase cell cycle arrest<br>2- Apoptosis induction<br>3- Autophagy induction<br>4- Inhibition of tumor growth | [254] |

[1] Nanostructured lipid carrier

**Table 4.** Combinational therapies-based statins in GBM.

| Combinational therapy | Type of study | Dose of administration | Main mechanism (s) | Reference (s) |
|---|---|---|---|---|
| Atorvastatin + TMZ | *In vitro*[1]<br>*In vivo*[2] | 5, 10, and 20 μM | 1- A dose-dependent cell proliferation inhibition<br>2- Inhibition of protein prenylation<br>3- Suppressing the Ras activation, leading to decreased activation of Ras and its downstream signaling pathways, including ERK, rS6, and eIF4E | [113] |
| Atorvastatin + TMZ | *Clinical trial*[3] | Maintenance dose: 80 mg PO daily until disease progression or unacceptable toxicity Loading dose: 40 mg PO daily for the first 21 days) | - | - |
| Atorvastatin + Biochanin A | *In vitro*[1] | - | 1- Reduced invasion<br>2- A decrease in glycolytic activity<br>3- An increase in mitochondrial respiration | [255] |
| Lovastatin + TMZ | *In vitro*[1] | 0–20 μM | 1- Enhancing the cytotoxicity of TMZ<br>2- An increase the TMZ-induced cellular apoptosis<br>3- Impair the autophagic flux via the inhibition of the Akt/mTOR signaling pathway<br>4- Suppression of autophagosome-lysosome fusion machinery | [127] |
| Fluvastatin + celecoxib | *Clinical trial*[4] | Escalation dose: Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day. | - | - |
| Simvastatin + fenretinide[5] | *In vitro*[1]<br>*In vivo*[2] | 0–20 μM | 1- Repolarizing the tumor-associated macrophages from the M2 phenotype to M1 via regulating the STAT6 pathway<br>2- Inducing the ROS-mediated mitochondrial apoptosis by inhibiting the Ras/Raf/p-ERK pathway | [256] |
| Lovastatin + gefitinib | *In vitro*[1] | Lovastatin: 0–25 μM<br>Gefitinib: 0–25 μM | 1- Enhancing the sensitivity of GBM cells to the EGFR kinase inhibitor gefitinib<br>2- Inducing potent synergistic cytotoxicity, irrespective of EGFRvIII and PTEN status | [257] |
| Lovastatin + IR | *In vitro*[1] | Lovastatin: 5–50 μM<br>IRR: 4 Gy | 1- A decrease in clonogenicity and cell number<br>2- Inducing cell cycle arrest | [258] |
| Atorvastatin or lovastatin + pioglitazone | *In vitro*[1]<br>*In vivo*[2] | *In vitro*:<br>Lovastatin: 5 μM<br>Atorvastatin 1.5 μM<br>pioglitazone: 5 and 40 μM<br>*In vivo*: Atorvastatin: 40 mg/kg<br>Lovastatin: 50 mg/kg<br>Pioglitazone: 5 mg/kg | 1- A marked increase in caspase 3 activity<br>2- Significant reduction in tumor volume by approximately 40% | [16, 259] |
| Pitavastatin + irinotecan | *In vitro*<br>*In vivo* | *In vitro:*<br>Pitavastatin: 0–10 μM<br>Irinotecan: 0–10 μM<br>*In vivo:* | 1- Inducing cell death<br>2- Inducing autophagy<br>3- Suppression of MDR-1<br>4- Enhancing antitumor efficacy | [131] |
| | | low dose of pitavastatin: 0.5 mg/kg<br>Irinotecan: 0.5–5 mg/kg | 5- Lowering the $IC_{50}$ values for irinotecan by 40- to 70-fold<br>6- Arresting in the G0/G1 phase | |

[1]A172, T98G, DBTRG, MO59 J, U118, LN 405, LN443, Stem cell-like GBM, rat RG II, U87 MG, and U251 GBM

cells

[2]Subcutaneous injection of GBM cells (xenograft mouse model)

[3]A phase II of a clinical trial (NCT02029573)

[4]A phase I of a clinical trial (NCT02115074)

[5]The drugs were co-encapsulated into a TPGS-TAT-embedded lactoferrin nanoparticle system

## References:


[1] S. Sahab-Negah, F. Ariakia, M. Jalili-Nik, A.R. Afshari, S. Salehi, F. Samini, G. Rajabzadeh, A. Gorji, Curcumin Loaded in Niosomal Nanoparticles Improved the Anti-tumor Effects of Free Curcumin on Glioblastoma Stem-like Cells: an In Vitro Study, MOLECULAR NEUROBIOLOGY (2020).

[2] H. Mollazadeh, E. Mohtashami, S. Mousavi, M. Soukhtanloo, M. Vahedi, A. Hosseini, A. Afshari, A.J.C.P.D. Sahebkar, Deciphering the role of glutamate signaling in glioblastoma multiforme: current therapeutic modalities and future directions, (2020).

[3] E. Tavana, H. Mollazadeh, E. Mohtashami, S.M.S. Modaresi, A. Hosseini, H. Sabri, A. Soltani, H. Javid, A.R. Afshari, A. Sahebkar, Quercetin: A promising phytochemical for the treatment of glioblastoma multiforme, BioFactors (2019).

[4] S. Sahab-Negah, F. Ariakia, M. Jalili-Nik, A.R. Afshari, S. Salehi, F. Samini, G. Rajabzadeh, A.J.M.N. Gorji, Curcumin Loaded in Niosomal Nanoparticles Improved the Anti-tumor Effects of Free Curcumin on Glioblastoma Stem-like Cells: an In Vitro Study, (2020).

[5] L. Liberale, F. Carbone, F. Montecucco, A. Sahebkar, Statins reduce vascular inflammation in atherogenesis: A review of underlying molecular mechanisms, The International Journal of Biochemistry & Cell Biology (2020) 105735.

[6] T. Johnston, T. Korolenko, M. Pirro, A. Sahebkar, Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management, Pharmacological research 120 (2017) 219-225.

[7] B.A. Dickerman, X. García-Albéniz, R.W. Logan, S. Denaxas, M.A. Hernán, Avoidable flaws in observational analyses: an application to statins and cancer, Nature medicine 25(10) (2019) 1601-1606.

[8] A. Askarizadeh, A.E. Butler, A. Badiee, A. Sahebkar, Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal, Journal of cellular physiology 234(2) (2019) 1219-1229.

[9] A. Bahrami, S. Bo, T. Jamialahmadi, A. Sahebkar, Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms, Ageing Research Reviews (2020) 101024.

[10] L. Zhang, T. Chen, Y. Dou, S. Zhang, H. Liu, T. Khishignyam, X. Li, D. Zuo, Z. Zhang, M. Jin, Atorvastatin exerts antileukemia activity via inhibiting mevalonate-YAP axis in K562 and HL60 cells, Frontiers in oncology 9 (2019) 1032.

[11] C.H. Beckwitt, K. Shiraha, A. Wells, Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling, PLoS One 13(5) (2018).

[12] A. Wang, H.A. Wakelee, A.K. Aragaki, J.Y. Tang, A.W. Kurian, J.E. Manson, M.L. Stefanick, Protective effects of statins in cancer: should they be prescribed for high-risk patients?, Current atherosclerosis reports 18(12) (2016) 72.

[13] P.W. Voorneveld, M.S. Reimers, E. Bastiaannet, R.J. Jacobs, R. van Eijk, M.M. Zanders, R.M. Herings, M.P. van Herk-Sukel, L.L. Kodach, T. van Wezel, Statin use after diagnosis of colon cancer and patient survival, Gastroenterology 153(2) (2017) 470-479. e4.

[14] G. Papadopoulos, D. Delakas, L. Nakopoulou, T. Kassimatis, Statins and prostate cancer: molecular and clinical aspects, European Journal of cancer 47(6) (2011) 819-830.
[15] S. Galland, P. Martin, G. Fregni, I. Letovanec, I. Stamenkovic, Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins, Cancer Letters (2020).
[16] J.H. Tapia-Pérez, E. Kirches, C. Mawrin, R. Firsching, T. Schneider, Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells, Cancer chemotherapy and pharmacology 67(5) (2011) 1193-1201.
[17] A.O. Sodero, F.J. Barrantes, Pleiotropic effects of statins on brain cells, Biochimica et Biophysica Acta (BBA)-Biomembranes (2020) 183340.
[18] M. Yanae, M. Tsubaki, T. Satou, T. Itoh, M. Imano, Y. Yamazoe, S. Nishida, Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma, Journal of Experimental & Clinical Cancer Research 30(1) (2011) 74.
[19] E. Miraglia, J. Högberg, U. Stenius, Statins exhibit anticancer effects through modifications of the pAkt signaling pathway, International journal of oncology 40(3) (2012) 867-875.
[20] Y. Xie, Q. Lu, C. Lenahan, S. Yang, D. Zhou, X. Qi, Whether statin use improves the survival of patients with glioblastoma?: A meta-analysis, Medicine 99(9) (2020) e18997.
[21] D. Gaist, J. Hallas, S. Friis, S. Hansen, H.T. Sørensen, Statin use and survival following glioblastoma multiforme, Cancer epidemiology 38(6) (2014) 722-727.
[22] M. Osmak, Statins and cancer: current and future prospects, Cancer letters 324(1) (2012) 1-12.
[23] N. G Vallianou, A. Kostantinou, M. Kougias, C. Kazazis, Statins and cancer, Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 14(5) (2014) 706-712.
[24] U. Laufs, H. Kilter, C. Konkol, S. Wassmann, M. Böhm, G.J.C.r. Nickenig, Impact of HMG CoA reductase inhibition on small GTPases in the heart, 53(4) (2002) 911-920.
[25] H. Mo, R. Jeter, A. Bachmann, S.T. Yount, C.-L. Shen, H. Yeganehjoo, The potential of isoprenoids in adjuvant cancer therapy to reduce adverse effects of statins, Frontiers in pharmacology 9 (2019) 1515.
[26] S. Matzno, S. Yasuda, S. Juman, Y. Yamamoto, N. Nagareya- Ishida, T. Nakabayashi, K. Matsuyama, K. Tazuya- Murayama, Statin- induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein, Journal of pharmacy and pharmacology 57(11) (2005) 1475-1484.
[27] A. Göbel, M. Rauner, L.C. Hofbauer, T.D. Rachner, Cholesterol and beyond-The role of the mevalonate pathway in cancer biology, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1873(2) (2020) 188351.
[28] F. Röhrig, A. Schulze, The multifaceted roles of fatty acid synthesis in cancer, Nature Reviews Cancer 16(11) (2016) 732.
[29] S. Lavu, T.M. Therneau, W.S. Harmsen, K.C. Mara, N. Wongjarupong, M. Hassan, H.A. Ali, S. Antwi, N.H. Giama, K. Miyabe, Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma, Hepatology (2020).
[30] Y.-C. Chou, C.-H. Lin, C.-S. Wong, W.-Y. Chou, J.-Y. Chang, C.-A. Sun, Statin use and the risk of renal cell carcinoma: national cohort study, Journal of Investigative Medicine 68(3) (2020) 776-781.

[31] E. Jian-Yu, S.-E. Lu, Y. Lin, J.M. Graber, D. Rotter, L. Zhang, G.M. Petersen, K. Demissie, G. Lu-Yao, X.-L. Tan, Differential and joint effects of metformin and statins on overall survival of elderly patients with pancreatic adenocarcinoma: a large population-based study, Cancer Epidemiology and Prevention Biomarkers 26(8) (2017) 1225-1232.
[32] T.G. Simon, A.-S. Duberg, S. Aleman, H. Hagstrom, L.H. Nguyen, H. Khalili, R.T. Chung, J.F. Ludvigsson, Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: Results from a nationwide Swedish population, Annals of internal medicine 171(5) (2019) 318-327.
[33] L. von Schuckmann, K. Khosrotehrani, R. Ghiasvand, M. Hughes, J. van der Pols, M. Malt, B. Smithers, A.C. Green, Statins may reduce disease recurrence in patients with ulcerated primary melanoma, British Journal of Dermatology (2020).
[34] D.-K. Xia, Z.-G. Hu, Y.-F. Tian, F.-J. Zeng, Statin use and prognosis of lung cancer: a systematic review and meta-analysis of observational studies and randomized controlled trials, Drug design, development and therapy 13 (2019) 405.
[35] P.O. Richard, A.E. Ahmad, S. Bashir, R.J. Hamilton, R.K. Nam, R. Leao, C. Jeldres, G.S. Kulkarni, Effect of statins as a secondary chemopreventive agent among individuals with non–muscle-invasive bladder cancer: A population-based analysis, Urologic Oncology: Seminars and Original Investigations, Elsevier, 2017, pp. 342-348.
[36] B.P. Rutledge, P. Desai, S. Liu, J. Luo, R. Nassir, Q. Lihong, M. Arun, M. Abdel‐Rasoul, M.S. Simon, The association between statins and colorectal cancer stage in the Women's Health Initiative, Molecular and Clinical Oncology 11(3) (2019) 252-258.
[37] K. Hayashi, Y. Nakazato, N. Morito, M. Sagi, T. Fujita, N. Anzai, M. Chida, Fluvastatin is effective against thymic carcinoma, Life Sciences 240 (2020) 117110.
[38] P. Tan, C. Zhang, S.-Y. Wei, Z. Tang, L. Gao, L. Yang, Q. Wei, Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review, Asian journal of andrology 19(6) (2017) 666.
[39] V.H. Jayalath, M. Nayan, A. Finelli, M. Komisarenki, N. Timilshina, G.S. Kulkarni, N.E. Fleshner, B. Bhindi, A. Evans, A.R. Zlotta, Statin use and time to progression in men on active surveillance for prostate cancer, Prostate cancer and prostatic diseases 21(4) (2018) 509.
[40] O. Gaber, I. Eldessouki, R. Hassan, M. Magdy, J.C. Morris, N.A. Karim, Retrospective Study of the Effect of Statins on the Outcome of Lung Cancer Patients, University of Cincinnati Experience, Asian Pacific journal of cancer prevention: APJCP 20(8) (2019) 2391.
[41] S.F. Nielsen, B.G. Nordestgaard, S.E.J.N.E.J.o.M. Bojesen, Statin use and reduced cancer-related mortality, 367(19) (2012) 1792-1802.
[42] D.M. Boudreau, O. Yu, J. Johnson, Statin use and cancer risk: a comprehensive review, Expert opinion on drug safety 9(4) (2010) 603-621.
[43] B. Liu, Z. Yi, X. Guan, Y.-X. Zeng, F. Ma, The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis, Springer, 2017.
[44] M. Sakellakis, K. Akinosoglou, A. Kostaki, D. Spyropoulou, A. Koutras, Statins and risk of breast cancer recurrence, Breast Cancer: Targets and Therapy 8 (2016) 199.
[45] D.M. Boudreau, O. Yu, J.J.E.o.o.d.s. Johnson, Statin use and cancer risk: a comprehensive review, 9(4) (2010) 603-621.
[46] M.C. Vázquez-Borrego, A.C. Fuentes-Fayos, A.D. Herrera-Martínez, E. Venegas-Moreno, L. Fernando, A. Fanciulli, P. Moreno-Moreno, M.R. Alhambra-Expósito, A. Barrera-Martín, E. Dios, Statins directly regulate pituitary cell function and exert antitumor effects in pituitary tumors, Neuroendocrinology (2020).

[47] S.T. Kochuparambil, B. Al-Husein, A. Goc, S. Soliman, P.R. Somanath, Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression, Journal of Pharmacology and Experimental Therapeutics 336(2) (2011) 496-505.
[48] C.F. Warren, M.W. Wong-Brown, N.A. Bowden, BCL-2 family isoforms in apoptosis and cancer, Cell death & disease 10(3) (2019) 1-12.
[49] C.-W. Chou, C.-H. Lin, T.-H. Hsiao, C.-C. Lo, C.-Y. Hsieh, C.-C. Huang, Y.-P. Sher, Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis, Scientific Reports 9(1) (2019) 1-12.
[50] P. Cafforio, F. Dammacco, A. Gernone, F. Silvestris, Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells, Carcinogenesis 26(5) (2005) 883-891.
[51] F. Iannelli, R. Lombardi, M.R. Milone, B. Pucci, S. De Rienzo, A. Budillon, F. Bruzzese, Targeting mevalonate pathway in cancer treatment: repurposing of statins, Recent patents on anti-cancer drug discovery 13(2) (2018) 184-200.
[52] A.F. Hassanabad, S.A. McBride, Statins as potential therapeutics for lung cancer: molecular mechanisms and clinical outcomes, American journal of clinical oncology 42(9) (2019) 732-736.
[53] W.G. Wood, U. Igbavboa, W.E. Muller, G.P. Eckert, Statins, Bcl-2, and apoptosis: cell death or cell protection?, Molecular neurobiology 48(2) (2013) 308-314.
[54] M. Kamigaki, T. Sasaki, M. Serikawa, M. Inoue, K. Kobayashi, H. Itsuki, T. Minami, M. Yukutake, A. Okazaki, T. Ishigaki, Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells, International journal of oncology 39(3) (2011) 561-568.
[55] S.J. Cho, J.S. Kim, J.M. Kim, J.Y. Lee, H.C. Jung, I.S. Song, Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis- associated colon cancer in mice, International journal of cancer 123(4) (2008) 951-957.
[56] M. Koyuturk, M. Ersoz, N. Altiok, Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK, Cancer letters 250(2) (2007) 220-228.
[57] A. Hoque, H. Chen, X.-c. Xu, Statin induces apoptosis and cell growth arrest in prostate cancer cells, Cancer Epidemiology and Prevention Biomarkers 17(1) (2008) 88-94.
[58] D. Fujiwara, M. Tsubaki, T. Takeda, Y. Tomonari, Y.-i. Koumoto, K. Sakaguchi, S. Nishida, Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells, Tumor Biology 39(10) (2017) 1010428317734947.
[59] A.C. Knapp, J. Huang, G. Starling, P.A. Kiener, Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death, Atherosclerosis 152(1) (2000) 217-227.
[60] G. Sarrabayrouse, C. Synaeve, K. Leveque, G. Favre, A.-F. Tilkin-Mariamé, Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells, Neoplasia (New York, NY) 9(12) (2007) 1078.
[61] A. Goc, S.T. Kochuparambil, B. Al-Husein, A. Al-Azayzih, S. Mohammad, P.R. Somanath, Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis, BMC cancer 12(1) (2012) 409.
[62] S. Dehnavi, N. Sohrabi, M. Sadeghi, P. Lansberg, M. Banach, K. Al-Rasadi, T.P. Johnston, A.J.P. Sahebkar, Therapeutics, Statins and autoimmunity: State-of-the-art, (2020) 107614.

[63] A. Göbel, M. Rauner, L.C. Hofbauer, T.D.J.B.e.B.A.-R.o.C. Rachner, Cholesterol and beyond-The role of the mevalonate pathway in cancer biology, 1873(2) (2020) 188351.
[64] M. Thurnher, O. Nussbaumer, G. Gruenbacher, Novel aspects of mevalonate pathway inhibitors as antitumor agents, Clinical Cancer Research 18(13) (2012) 3524-3531.
[65] M.H. Lee, Y.S. Cho, Y.M. Han, Simvastatin suppresses self- renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation, Stem Cells 25(7) (2007) 1654-1663.
[66] V.B. Wali, S.V. Bachawal, P.W. Sylvester, Combined treatment of γ-tocotrienol with statins induce mammary tumor cell cycle arrest in G1, Experimental Biology and Medicine 234(6) (2009) 639-650.
[67] L. Matusewicz, J. Meissner, M. Toporkiewicz, A.F. Sikorski, The effect of statins on cancer cells, Tumor Biology 36(7) (2015) 4889-4904.
[68] J. Davignon, L. Mabile, Mechanisms of action of statins and their pleiotropic effects, Annales d'endocrinologie, 2001, pp. 101-112.
[69] C.A. Sánchez, E. Rodriguez, E. Varela, E. Zapata, A. Paez, F.A. Massó, L.F. Montaño, R. Lopez-Marure, Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress, Cancer investigation 26(7) (2008) 698-707.
[70] A.P. Sutter, K. Maaser, M. Höpfner, A. Huether, D. Schuppan, H. Scherübl, Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor, Journal of hepatology 43(5) (2005) 808-816.
[71] T. Wang, S. Seah, X. Loh, C.-W. Chan, M. Hartman, B.-C. Goh, S.-C. Lee, Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway, Oncotarget 7(3) (2016) 2532.
[72] G. Wang, R. Cao, Y. Wang, G. Qian, H.C. Dan, W. Jiang, L. Ju, M. Wu, Y. Xiao, X. Wang, Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway, Scientific reports 6 (2016) 35783.
[73] S. Kany, M. Woschek, N. Kneip, R. Sturm, M. Kalbitz, M. Hanschen, B. Relja, Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation, International journal of oncology 52(4) (2018) 1285-1294.
[74] Z. Ma, W. Wang, Y. Zhang, M. Yao, L. Ying, L. Zhu, Inhibitory effect of simvastatin in nasopharyngeal carcinoma cells, Experimental and therapeutic medicine 17(6) (2019) 4477-4484.
[75] M.A. Ingersoll, D.R. Miller, O. Martinez, C.B. Wakefield, K.-C. Hsieh, M.V. Simha, C.-L. Kao, H.-T. Chen, S.K. Batra, M.-F. Lin, Statin derivatives as therapeutic agents for castration-resistant prostate cancer, Cancer letters 383(1) (2016) 94-105.
[76] S. Aldalaen, R.I. El-Gogary, M. Nasr, Fabrication of rosuvastatin-loaded polymeric nanocapsules: a promising modality for treating hepatic cancer delineated by apoptotic and cell cycle arrest assessment, Drug development and industrial pharmacy 45(1) (2019) 55-62.
[77] K. Gash, A. Chambers, D. Cotton, A. Williams, M. Thomas, Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy, British journal of cancer 117(2) (2017) 210-219.
[78] M.M. Kozak, E.M. Anderson, R. Von Eyben, J.S. Pai, G.A. Poultsides, B.C. Visser, J.A. Norton, A.C. Koong, D.T. Chang, Statin and metformin use prolongs survival in patients with resectable pancreatic cancer, Pancreas 45(1) (2016) 64-70.

[79] J. Cloos, G.J. Peters, M. Al, Y.G. Assaraf, L. Wang, J.W. Singer, J.E. Cortes, G.J. Ossenkoppele, G. Jansen, Statins Potentiate Aminopeptidase Inhibitor (pro) Drug Activity in Acute Myeloid Leukemia Cells, Blood 132(Supplement 1) (2018) 3945-3945.
[80] J. Cortes, E. Feldman, K. Yee, D. Rizzieri, A.S. Advani, A. Charman, R. Spruyt, M. Toal, H. Kantarjian, Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study, The Lancet Oncology 14(4) (2013) 354-362.
[81] A. Palko-Łabuz, K. Środa-Pomianek, O. Wesołowska, E. Kostrzewa-Susłow, A. Uryga, K. Michalak, MDR reversal and pro-apoptotic effects of statins and statins combined with flavonoids in colon cancer cells, Biomedicine & Pharmacotherapy 109 (2019) 1511-1522.
[82] A. Sahebkar, L. Simental- Mendía, F. Guerrero- Romero, J. Golledge, G. Watts, Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta- analysis of clinical trials, Diabetes, Obesity and Metabolism 17(11) (2015) 1042-1055.
[83] A.A. Momtazi, M. Banach, M. Pirro, N. Katsiki, A. Sahebkar, Regulation of PCSK9 by nutraceuticals, Pharmacological research 120 (2017) 157-169.
[84] A.A. Momtazi-Borojeni, M.E. Nik, M.R. Jaafari, M. Banach, A.J.A.o.m.s.A. Sahebkar, Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer, 15(3) (2019) 559.
[85] Z. Dong, W. Zhang, S. Chen, C. Liu, Silibinin A decreases statin‐induced PCSK9 expression in human hepatoblastoma HepG2 cells, Molecular medicine reports 20(2) (2019) 1383-1392.
[86] K. Środa-Pomianek, K. Michalak, A. Palko-Łabuz, A. Uryga, P. Świątek, M. Majkowski, O. Wesołowska, The Combined Use of Phenothiazines and Statins Strongly Affects Doxorubicin-Resistance, Apoptosis, and Cox-2 Activity in Colon Cancer Cells, International journal of molecular sciences 20(4) (2019) 955.
[87] H.-D. Um, Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species, Oncotarget 7(5) (2016) 5193.
[88] C.H. Beckwitt, A.M. Clark, B. Ma, D. Whaley, Z.N. Oltvai, A. Wells, Statins attenuate outgrowth of breast cancer metastases, British journal of cancer 119(9) (2018) 1094-1105.
[89] A. Göbel, M. Rauner, L.C. Hofbauer, T.D. Rachner, Cholesterol and beyond-The role of the mevalonate pathway in cancer biology, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer (2020) 188351.
[90] S.-H. Moon, C.-H. Huang, S.L. Houlihan, K. Regunath, W.A. Freed-Pastor, J.P. Morris IV, D.F. Tschaharganeh, E.R. Kastenhuber, A.M. Barsotti, R. Culp-Hill, p53 represses the mevalonate pathway to mediate tumor suppression, Cell 176(3) (2019) 564-580. e19.
[91] A.J. Ridley, Rho proteins and cancer, Breast cancer research and treatment 84(1) (2004) 13-19.
[92] S. Narumiya, M. Tanji, T. Ishizaki, Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion, Cancer and Metastasis Reviews 28(1-2) (2009) 65-76.
[93] H.M. Jones, Z. Fang, W. Sun, L.H. Clark, J.E. Stine, A.-Q. Tran, S.A. Sullivan, T.P. Gilliam, C. Zhou, V.L. Bae-Jump, Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro, American journal of cancer research 7(12) (2017) 2478.
[94] B. Buranrat, L. Senggunprai, A. Prawan, V. Kukongviriyapan, Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells, Life sciences 153 (2016) 41-49.

[95] J.E. Stine, H. Guo, X. Sheng, X. Han, M.N. Schointuch, T.P. Gilliam, P.A. Gehrig, C. Zhou, V.L. Bae-Jump, The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer, Oncotarget 7(1) (2016) 946.
[96] M.-C. Chen, Y.-C. Tsai, J.-H. Tseng, -.J. Liou Jr, S. Horng, H.-C. Wen, Y.-C. Fan, W.-B. Zhong, S.-P. Hsu, Simvastatin inhibits cell proliferation and migration in human anaplastic thyroid cancer, International journal of molecular sciences 18(12) (2017) 2690.
[97] I. Georgakopoulos-Soares, D.V. Chartoumpekis, V. Kyriazopoulou, A. Zaravinos, EMT factors and metabolic pathways in cancer, Frontiers in Oncology 10 (2020) 499.
[98] S. Koohestanimobarhan, S. Salami, V. Imeni, Z. Mohammadi, O. Bayat, Lipophilic statins antagonistically alter the major epithelial- to- mesenchymal transition signaling pathways in breast cancer stem–like cells via inhibition of the mevalonate pathway, Journal of cellular biochemistry 120(2) (2019) 2515-2531.
[99] Z. Fan, H. Jiang, Z. Wang, J. Qu, Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1, Oncology reports 36(2) (2016) 1016-1022.
[100] Q. Ma, Y. Gao, P. Xu, K. Li, X. Xu, J. Gao, Y. Qi, J. Xu, Y. Yang, W. Song, Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB), BioMed research international 2019 (2019).
[101] H. Yamaguchi, J. Condeelis, Regulation of the actin cytoskeleton in cancer cell migration and invasion, Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1773(5) (2007) 642-652.
[102] C.D. Lawson, A.J. Ridley, Rho GTPase signaling complexes in cell migration and invasion, Journal of Cell Biology 217(2) (2018) 447-457.
[103] R. Tatè, E. Zona, R. De Cicco, V. Trotta, M. Urciuoli, A. Morelli, S. Baiano, R. Carnuccio, M.P. Fuggetta, F. Morelli, Simvastatin inhibits the expression of stemness‐related genes and the metastatic invasion of human cancer cells via destruction of the cytoskeleton, International journal of oncology 51(6) (2017) 1851-1859.
[104] P.M. Biselli-Chicote, A.T. Lotierzo, J.M. Biselli, É.C. Paravino, E.M. Goloni-Bertollo, Atorvastatin increases oxidative stress and inhibits cell migration of oral squamous cell carcinoma in vitro, Oral oncology 90 (2019) 109-114.
[105] I. Goossens-Beumer, E. Zeestraten, A. Benard, T. Christen, M. Reimers, R. Keijzer, C. Sier, G. Liefers, H. Morreau, H. Putter, Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer, British journal of cancer 110(12) (2014) 2935-2944.
[106] W.Y. Cai, Y. Zhuang, F. Yan, T. Li, W.T. Song, J.H. Sun, Effect of survivin downregulation by simvastatin on the growth and invasion of salivary adenoid cystic carcinoma, Molecular medicine reports 18(2) (2018) 1939-1946.
[107] M. Soukhtanloo, E. Mohtashami, A. Maghrouni, H. Mollazadeh, S.H. Mousavi, M.K. Roshan, S.-A. Tabatabaeizadeh, A. Hosseini, M.M. Vahedi, M. Jalili-Nik, Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway, Pharmacological reports (2020) 1-11.
[108] H. Mollazadeh, E. Mohtashami, S. Mousavi, M. Soukhtanloo, M. Vahedi, A. Hosseini, A. Afshari, A. Sahebkar, Deciphering the role of glutamate signaling in glioblastoma multiforme: current therapeutic modalities and future directions, Current Pharmaceutical Design (2020).

[109] A.R. Afshari, H. Mollazadeh, E. Mohtashami, A. Soltani, M. Soukhtanloo, A. Hosseini, M. Jalili-Nik, M.M. Vahedi, M.K. Roshan, A.J.C.m.c. Sahebkar, Protective role of natural products in glioblastoma multiforme: a focus on nitric oxide pathway, (2020).
[110] A.R. Afshari, M. Jalili-Nik, M. Soukhtanloo, A. Ghorbani, H.R. Sadeghnia, H. Mollazadeh, M.K. Roshan, F. Rahmani, H. Sabri, M.M. Vahedi, Auraptene-induced cytotoxicity mechanisms in human malignant glioblastoma (U87) cells: role of reactive oxygen species (ROS), EXCLI Journal 18 (2019) 576-590.
[111] J. Alizadeh, A.A. Zeki, N. Mirzaei, S. Tewary, A.R. Moghadam, A. Glogowska, P. Nagakannan, E. Eftekharpour, E. Wiechec, J.W. Gordon, Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells, Scientific reports 7(1) (2017) 1-14.
[112] S. Shojaei, J. Alizadeh, J. Thliveris, N. Koleini, E. Kardami, G.M. Hatch, F. Xu, S. Hombach-Klonisch, T. Klonisch, S. Ghavami, Statins: a new approach to combat temozolomide chemoresistance in glioblastoma, Journal of Investigative Medicine 66(8) (2018) 1083-1087.
[113] P. Peng, W. Wei, C. Long, J. Li, Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling, Biochemical and biophysical research communications 489(3) (2017) 293-298.
[114] S. Bhavsar, K. Hagan, R. Arunkumar, Y. Potylchansky, R. Grasu, A. Dang, R. Carlson, C. Cowels, B. Arnold, T.F. Rahlfs, Preoperative statin use is not associated with improvement in survival after glioblastoma surgery, Journal of Clinical Neuroscience 31 (2016) 176-180.
[115] A. Gupta, W. Stokes, M. Eguchi, M. Hararah, A. Amini, A. Mueller, R. Morgan, C. Bradley, D. Raben, J. McDermott, Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer, Oral oncology 90 (2019) 54-66.
[116] R.J. Hopkins, R.P. Young, Mevalonate signaling, COPD and cancer: the statins and beyond, Journal of Investigative Medicine 67(4) (2019) 711-714.
[117] G. Fritz, C. Henninger, J. Huelsenbeck, Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents, British medical bulletin 97(1) (2011) 17-26.
[118] M. Weis, C. Heeschen, A.J. Glassford, J.P.J.C. Cooke, Statins have biphasic effects on angiogenesis, 105(6) (2002) 739-745.
[119] J. Dulak, A.J.C.c.d.t. Józkowicz, Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy, 5(8) (2005) 579-594.
[120] L. Björkhem- Bergman, J.D. Lindh, P. Bergman, What is a relevant statin concentration in cell experiments claiming pleiotropic effects?, British journal of clinical pharmacology 72(1) (2011) 164-165.
[121] Y. Yamamoto, A. Tomiyama, N. Sasaki, H. Yamaguchi, T. Shirakihara, K. Nakashima, K. Kumagai, S. Takeuchi, T. Toyooka, N. Otani, Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft, Biochemical and biophysical research communications 495(1) (2018) 1292-1299.
[122] P.M. Tricarico, S. Crovella, F. Celsi, Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link, International journal of molecular sciences 16(7) (2015) 16067-16084.
[123] T.P. Miettinen, M. Björklund, The mevalonate pathway as a metabolic requirement for autophagy–implications for growth control, proteostasis, and disease, Molecular & cellular oncology 3(3) (2016) e1143546.

[124] T. Kanzawa, I. Germano, T. Komata, H. Ito, Y. Kondo, S. Kondo, Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells, Cell Death & Differentiation 11(4) (2004) 448-457.
[125] S. Shojaei, J. Alizadeh, J. Thliveris, N. Koleini, E. Kardami, G. Hatch, F. Xu, S. Hombach-Klonisch, T. Klonisch, S. Ghavami, Inhibition of autophagy by mevalonate pathway inhibitors, a new therapeutic approach to sensitize glioblastoma cells to temozolomide induced apoptosis, The FASEB Journal 32(1_supplement) (2018) 533.41-533.41.
[126] P. Jiang, R. Mukthavaram, Y. Chao, N. Nomura, I. Bharati, V. Fogal, S. Pastorino, D. Teng, X. Cong, S. Pingle, In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells, British journal of cancer 111(8) (2014) 1562-1571.
[127] Z. Zhu, P. Zhang, N. Li, K.M.Y. Kiang, S.Y. Cheng, V.K.-W. Wong, G.K.-K. Leung, Lovastatin enhances cytotoxicity of temozolomide via impairing autophagic flux in glioblastoma cells, BioMed research international 2019 (2019).
[128] S. Shojaei, N. Koleini, E. Samiei, M. Aghaei, L.K. Cole, J. Alizadeh, M.I. Islam, A.r. Vosoughi, M. Albokashy, Y. Butterfield, Simvastatin increases temozolomide- induced cell death by targeting the fusion of autophagosomes and lysosomes, The FEBS journal 287(5) (2020) 1005-1034.
[129] K.A. Oliveira, T. Dal-Cim, F.G. Lopes, F.K. Ludka, C.B. Nedel, C.I. Tasca, Atorvastatin promotes cytotoxicity and reduces migration and proliferation of human A172 glioma cells, Molecular neurobiology 55(2) (2018) 1509-1523.
[130] M. Misirkic, K. Janjetovic, L. Vucicevic, G. Tovilovic, B. Ristic, U. Vilimanovich, L. Harhaji-Trajkovic, M. Sumarac-Dumanovic, D. Micic, V. Bumbasirevic, Inhibition of AMPK-dependent autophagy enhances in vitro antiglioma effect of simvastatin, Pharmacological research 65(1) (2012) 111-119.
[131] P. Jiang, R. Mukthavavam, Y. Chao, I.S. Bharati, V. Fogal, S. Pastorino, X. Cong, N. Nomura, M. Gallagher, T. Abbasi, Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs, Journal of translational medicine 12(1) (2014) 13.
[132] D.Y. Chan, G.G. Chen, W.S. Poon, P.C. Liu, Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis, Journal of neuro-oncology 86(3) (2008) 273-283.
[133] Y. Liu, L. Chen, Z. Gong, L. Shen, C. Kao, J.M. Hock, L. Sun, X. Li, Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells, Oncotarget 6(5) (2015) 3055.
[134] P.C. Liu, G. Lu, Y. Deng, C.D. Wang, X.W. Su, J.Y. Zhou, T.M. Chan, X. Hu, W.S. Poon, Inhibition of NF-κB pathway and modulation of MAPK signaling pathways in glioblastoma and implications for lovastatin and tumor necrosis factor-related apoptosis inducing ligand (TRAIL) combination therapy, PloS one 12(1) (2017).
[135] N. Bayat, S. Ebrahimi-Barough, A. Norouzi-Javidan, H. Saberi, R. Tajerian, M.M.M. Ardakan, S. Shirian, A. Ai, J. Ai, Apoptotic effect of atorvastatin in glioblastoma spheroids tumor cultured in fibrin gel, Biomedicine & Pharmacotherapy 84 (2016) 1959-1966.
[136] N. Bayat, R. Izadpanah, S. Ebrahimi-Barough, A.N. Javidan, A. Ai, M.M.M. Ardakan, H. Saberi, J. Ai, The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: in 3D in Vitro Model, Asian Pacific journal of cancer prevention: APJCP 19(9) (2018) 2553.
[137] N. Bayat, R. Izadpanah, S. Ebrahimi-Barough, A. Norouzi-Javidan, H. Saberi, M.M.M. Ardakan, A. Ai, M. Soleimannejad, J. Ai, Anti-inflammatory Effects of Atorvastatin in Human

Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment, Molecular neurobiology 55(3) (2018) 2102-2110.
[138] A. Wawruszak, J. Kalafut, E. Okon, J. Czapinski, M. Halasa, A. Przybyszewska, P. Miziak, K. Okla, A. Rivero-Muller, A. Stepulak, Histone deacetylase inhibitors and phenotypical transformation of cancer cells, Cancers 11(2) (2019) 148.
[139] M.K. Ediriweera, K.H. Tennekoon, S.R. Samarakoon, Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents, Drug discovery today (2019).
[140] Y.-L. Chang, L.-C. Huang, Y.-C. Chen, Y.-W. Wang, D.-Y. Hueng, S.-M. Huang, The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines, The international journal of biochemistry & cell biology 92 (2017) 155-163.
[141] M.K. Roshan, A. Soltani, A. Soleimani, K.R. Kahkhaie, A.R. Afshari, M. Soukhtanloo, Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process, Biochimie (2019).
[142] B. Kaminska, M. Kocyk, M. Kijewska, TGF beta signaling and its role in glioma pathogenesis, Glioma Signaling, Springer2013, pp. 171-187.
[143] M. Lino, A. Merlo, PI3Kinase signaling in glioblastoma, Journal of neuro-oncology 103(3) (2011) 417-427.
[144] P. Maiti, J. Scott, D. Sengupta, A. Al-Gharaibeh, G.L. Dunbar, Curcumin and solid lipid curcumin particles induce autophagy, but inhibit mitophagy and the PI3K-Akt/mTOR pathway in cultured glioblastoma cells, International journal of molecular sciences 20(2) (2019) 399.
[145] Z. Jiang, X. Zheng, R.A. Lytle, R. Higashikubo, K.M. Rich, Lovastatin- induced up-regulation of the BH3- only protein, Bim, and cell death in glioblastoma cells, Journal of neurochemistry 89(1) (2004) 168-178.
[146] M. Koyuturk, M. Ersoz, N. Altiok, Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase, Neuroscience letters 370(2-3) (2004) 212-217.
[147] H. Wu, H. Jiang, D. Lu, Y. Xiong, C. Qu, D. Zhou, A. Mahmood, M. Chopp, Effect of simvastatin on glioma cell proliferation, migration, and apoptosis, Neurosurgery 65(6) (2009) 1087-1097.
[148] H. Al-Koussa, O.E. Atat, L. Jaafar, H. Tashjian, M. El-Sibai, The role of Rho GTPases in motility and invasion of glioblastoma cells, Analytical Cellular Pathology 2020 (2020).
[149] Z. Qiu, W. Yuan, T. Chen, C. Zhou, C. Liu, Y. Huang, D. Han, Q. Huang, HMGCR positively regulated the growth and migration of glioblastoma cells, Gene 576(1) (2016) 22-27.
[150] J. Gliemroth, H. Zulewski, H. Arnold, A.J.A. Terzis, Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin, Neurosurgical review 26(2) (2003) 117-124.
[151] O. Fromigué, Z. Hamidouche, P.J. Marie, Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion, Journal of Biological Chemistry 283(45) (2008) 30549-30556.
[152] N. Mahajan, V. Dhawan, Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells, Molecular and cellular biochemistry 338(1-2) (2010) 77-86.
[153] A. Sławińska-Brych, B. Zdzisińska, M. Kandefer-Szerszeń, Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line, Pharmacological Reports 66(1) (2014) 121-129.
[154] K.P. Sundararaj, D.J. Samuvel, Y. Li, A. Nareika, E.H. Slate, J.J. Sanders, M.F. Lopes-Virella, Y. Huang, Simvastatin suppresses LPS- induced MMP- 1 expression in U937

mononuclear cells by inhibiting protein isoprenylation- mediated ERK activation, Journal of leukocyte biology 84(4) (2008) 1120-1129.
[155] Y. Yongjun, H. Shuyun, C. Lei, C. Xiangrong, Y. Zhilin, K. Yiquan, Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression, Journal of neuroimmunology 260(1-2) (2013) 1-8.
[156] D. Rajshankar, B. Wang, E. Worndl, S. Menezes, Y. Wang, C.A. McCulloch, Focal adhesion kinase regulates tractional collagen remodeling, matrix metalloproteinase expression, and collagen structure, which in turn affects matrix- induced signaling, Journal of cellular physiology 235(3) (2020) 3096-3111.
[157] B. Deng, R. Liu, X. Tian, Z. Han, J. Chen, Simulated microgravity inhibits the viability and migration of glioma via fak/rhoa/rock and fak/nek2 signaling, In Vitro Cellular & Developmental Biology-Animal 55(4) (2019) 260-271.
[158] A. Kwiatkowska, M. Symons, Signaling determinants of glioma cell invasion, Glioma Signaling, Springer2020, pp. 129-149.
[159] S. Obara, M. Nakata, H. Takeshima, J.-i. Kuratsu, I. Maruyama, I. Kitajima, Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK), Cancer letters 185(2) (2002) 153-161.
[160] M. Nakada, D. Kita, L. Teng, I.V. Pyko, T. Watanabe, Y. Hayashi, J.-i. Hamada, Receptor tyrosine kinases: principles and functions in glioma invasion, Glioma Signaling, Springer2020, pp. 151-178.
[161] M. Tsubaki, Y. Yamazoe, M. Yanae, T. Satou, T. Itoh, J. Kaneko, Y. Kidera, K. Moriyama, S. Nishida, Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-β as angiogenic factors in mouse osteosarcoma, Cytokine 54(1) (2011) 100-107.
[162] A. Xiao, B. Brenneman, D. Floyd, L. Comeau, K. Spurio, I. Olmez, J. Lee, I. Nakano, J. Godlewski, A. Bronisz, Statins affect human glioblastoma and other cancers through TGF-β inhibition, Oncotarget 10(18) (2019) 1716.
[163] S.R. Bababeygy, N.V. Polevaya, S. Youssef, A. Sun, A. Xiong, T. Prugpichailers, A. Veeravagu, L.C. Hou, L. Steinman, V. Tse, HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model, Anticancer research 29(12) (2009) 4901-4908.
[164] S. Afshordel, B. Kern, J. Clasohm, H. König, M. Priester, J. Weissenberger, D. Kögel, G.P. Eckert, Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation–Impact of Ras-/Rho-prenylation, Pharmacological research 91 (2015) 69-77.
[165] M. Jakobisiak, J. Golab, Potential antitumor effects of statins, International journal of oncology 23(4) (2003) 1055-1069.
[166] J. Yarmolinsky, C.J. Bull, E.E. Vincent, J. Robinson, A. Walther, G.D. Smith, S.J. Lewis, C.L. Relton, R.M. Martin, Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian cancer, Jama 323(7) (2020) 646-655.
[167] D. Tamburrino, S. Crippa, S. Partelli, L. Archibugi, P.G. Arcidiacono, M. Falconi, G. Capurso, Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis, Digestive and Liver Disease (2020).
[168] N.A. Iarrobino, B. Gill, M.E. Bernard, M.V. Mishra, C.E. Champ, Targeting tumor metabolism with statins during treatment for advanced-stage pancreatic cancer, American journal of clinical oncology (2018).

[169] J.J. Lin, N. Ezer, K. Sigel, G. Mhango, J.P. Wisnivesky, The effect of statins on survival in patients with stage IV lung cancer, Lung Cancer 99 (2016) 137-142.
[170] M. Omori, Y. Okuma, T. Hakozaki, Y. Hosomi, Statins improve survival in patients previously treated with nivolumab for advanced non‐small cell lung cancer: An observational study, Molecular and clinical oncology 10(1) (2019) 137-143.
[171] B.K. Chen, H.-F. Chiu, C.-Y. Yang, Statins are Associated With a Reduced Risk of Brain Cancer: A Population-Based Case–Control Study, Medicine 95(17) (2016).
[172] S. Vuletic, R.G. Riekse, S.M. Marcovina, E.R. Peskind, W.R. Hazzard, J.J. Albers, Statins of different brain penetrability differentially affect CSF PLTP activity, Dementia and geriatric cognitive disorders 22(5-6) (2006) 392-398.
[173] C. Happold, T. Gorlia, L.B. Nabors, S.C. Erridge, D.A. Reardon, C. Hicking, M. Picard, R. Stupp, M. Weller, Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?, Journal of neuro-oncology 138(1) (2018) 163-171.
[174] C. Seliger, J. Schaertl, M. Gerken, C. Luber, M. Proescholdt, M.J. Riemenschneider, M.F. Leitzmann, P. Hau, M. Klinkhammer-Schalke, Use of statins or NSAIDs and survival of patients with high-grade glioma, PloS one 13(12) (2018).
[175] C. Seliger, C.R. Meier, C. Becker, S.S. Jick, U. Bogdahn, P. Hau, M.F. Leitzmann, Statin use and risk of glioma: population-based case–control analysis, European journal of epidemiology 31(9) (2016) 947-952.
[176] D.J. Cote, B.A. Rosner, S.A. Smith-Warner, K.M. Egan, M.J. Stampfer, Statin use, hyperlipidemia, and risk of glioma, European Journal of Epidemiology 34(11) (2019) 997-1011.
[177] A. Altwairgi, F. Alnajjar, H. Alhussain, E. Alsaeed, A. Balbaid, S. Aldandan, Y. Orz, A. Lary, W. Alghareeb, A. Alsharm, 53P Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report, Annals of Oncology 30(Supplement_9) (2019) mdz419.
[178] J. Larner, J. Jane, E. Laws, R. Packer, C. Myers, M. Shaffrey, A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme, American journal of clinical oncology 21(6) (1998) 579-583.
[179] J.S. Ferris, L. McCoy, A.I. Neugut, M. Wrensch, R. Lai, HMG CoA reductase inhibitors, NSAIDs and risk of glioma, International journal of cancer 131(6) (2012) E1031-E1037.
[180] P. Chruściel, A. Sahebkar, M. Rembek-Wieliczko, M.C. Serban, S. Ursoniu, D.P. Mikhailidis, S.R. Jones, S. Mosteoru, M.J. Blaha, S.S. Martin, J. Rysz, P.P. Toth, G.Y.H. Lip, M.J. Pencina, K.K. Ray, M. Banach, Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms, Atherosclerosis 253 (2016) 194-208.
[181] S.M.R. Parizadeh, M.R. Azarpazhooh, M. Moohebati, M. Nematy, M. Ghayour-Mobarhan, S. Tavallaie, A.A. Rahsepar, M. Amini, A. Sahebkar, M. Mohammadi, G.A.A. Ferns, Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial, Lipids 46(4) (2011) 333-340.
[182] A. Sahebkar, K. Kotani, C. Serban, S. Ursoniu, D.P. Mikhailidis, S.R. Jones, K.K. Ray, M.J. Blaha, J. Rysz, P.P. Toth, P. Muntner, G.Y.H. Lip, M. Banach, Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials, Atherosclerosis 241(2) (2015) 433-442.
[183] A. Sahebkar, C. Serban, D.P. Mikhailidis, A. Undas, G.Y.H. Lip, P. Muntner, V. Bittner, K.K. Ray, G.F. Watts, G.K. Hovingh, J. Rysz, J.J.P. Kastelein, M. Banach, Association between

statin use and plasma d-dimer levels: A systematic review and meta-analysis of randomised controlled trials, Thrombosis and Haemostasis 114(3) (2015) 546-557.
[184] C. Serban, A. Sahebkar, S. Ursoniu, D.P. Mikhailidis, M. Rizzo, G.Y.H. Lip, G. Kees Hovingh, J.J.P. Kastelein, L. Kalinowski, J. Rysz, M. Banach, A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations, Scientific Reports 5 (2015).
[185] M. Jalili-Nik, M.M. Sadeghi, E. Mohtashami, H. Mollazadeh, A.R. Afshari, A.J.O.M. Sahebkar, C. Longevity, Zerumbone Promotes Cytotoxicity in Human Malignant Glioblastoma Cells through Reactive Oxygen Species (ROS) Generation, 2020 (2020).
[186] H.J. Jang, E.M. Hong, S.W. Park, H.W. Byun, D.H. Koh, M.H. Choi, S.H. Kae, J. Lee, Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation, Oncology letters 12(1) (2016) 250-256.
[187] Z.A. Awan, U.A. Fahmy, S.M. Badr-Eldin, T.S. Ibrahim, H.Z. Asfour, M.W. Al-Rabia, A. Alfarsi, N.A. Alhakamy, W.H. Abdulaal, H.J.P. Al Sadoun, The Enhanced Cytotoxic and Pro-Apoptotic Effects of Optimized Simvastatin-Loaded Emulsomes on MCF-7 Breast Cancer Cells, 12(7) (2020) 597.
[188] X. Qi, L. Zheng, K. Lee, D. Kim, C. Kim, D. Cai, Z. Wu, J. Qin, Y. Yu, S.-K. Kim, HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway, Cell death & disease 4(2) (2013) e518-e518.
[189] C. Guijarro, L.M. Blanco-Colio, Z.A. Massy, M.P. O'Donnell, B.L. Kasiske, W.F. Keane, J. Egido, Lipophilic statins induce apoptosis of human vascular smooth muscle cells, Kidney International 56 (1999) S88-S91.
[190] M.A. Borahay, G.S. Kilic, C. Yallampalli, R.R. Snyder, G.D. Hankins, A. Al-Hendy, D. Boehning, Simvastatin potently induces calcium-dependent apoptosis of human leiomyoma cells, Journal of biological chemistry 289(51) (2014) 35075-35086.
[191] J.-L. Deng, R. Zhang, Y. Zeng, Y.-S. Zhu, G. Wang, Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells, Cancer Management and Research 11 (2019) 7231.
[192] H.-L. Chang, C.-Y. Chen, Y.-F. Hsu, W.-S. Kuo, G. Ou, P.-T. Chiu, Y.-H. Huang, M.-J. Hsu, Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade, Biochimica et Biophysica Acta (BBA)-General Subjects 1830(8) (2013) 4053-4064.
[193] H. Liu, S.-L. Liang, S. Kumar, C.M. Weyman, W. Liu, A. Zhou, Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression, Cancer chemotherapy and pharmacology 63(6) (2009) 997.
[194] K. Sheikholeslami, A. Ali Sher, S. Lockman, D. Kroft, M. Ganjibakhsh, K. Nejati-Koshki, S. Shojaei, S. Ghavami, M. Rastegar, Simvastatin induces apoptosis in medulloblastoma brain tumor cells via mevalonate cascade prenylation substrates, Cancers 11(7) (2019) 994.
[195] J. Longo, R.J. Hamilton, M. Masoomian, N. Khurram, E. Branchard, P.J. Mullen, M. Elbaz, K. Hersey, D. Chadwick, S.J.P.C. Ghai, P. Diseases, A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer, (2020) 1-8.
[196] K. Gauthaman, M. Richards, J. Wong, A. Bongso, Comparative evaluation of the effects of statins on human stem and cancer cells in vitro, Reproductive biomedicine online 15(5) (2007) 566-581.

[197] T.A. Martinez, N.D. Zeybek, S. Müftüoğlu, Evaluation of the cytotoxic and autophagic effects of atorvastatin on mcf-7 breast cancer cells, Balkan medical journal 35(3) (2018) 256.
[198] M.C. Sandoval-Usme, N. Ordóñez, A. Umaña-Pérez, L. Fernández-Pérez, M. Sánchez-Gómez, ANTI-TUMOR EFFECTS OF SIMVASTATIN ON UMR-106 OSTEOSARCOMA CELL LINE, Revista de la Academia Colombiana de Ciencias Exactas, Físicas y Naturales 35(136) (2011) 287-294.
[199] V.N. Ivanov, T.K. Hei, Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy, Apoptosis 16(12) (2011) 1268.
[200] O.O. Ogunwobi, I.L. Beales, Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells, American Journal of Gastroenterology 103(4) (2008) 825-837.
[201] J. Lee, E.M. Hong, J.A. Jang, S.W. Park, D.H. Koh, M.H. Choi, H.J. Jang, S.H. Kae, Simvastatin induces apoptosis and suppresses insulin-like growth factor 1 receptor in bile duct cancer cells, Gut and liver 10(2) (2016) 310.
[202] D. Chapman-Shimshoni, M. Yuklea, J. Radnay, H. Shapiro, M. Lishner, Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9, Experimental hematology 31(9) (2003) 779-783.
[203] W.A. Kamel, E. Sugihara, H. Nobusue, S. Yamaguchi-Iwai, N. Onishi, K. Maki, Y. Fukuchi, K. Matsuo, A. Muto, H. Saya, Simvastatin-induced apoptosis in osteosarcoma cells: a key role of RhoA-AMPK/p38 MAPK signaling in antitumor activity, Molecular cancer therapeutics 16(1) (2017) 182-192.
[204] H. Wang, N. Sun, X. Li, K. Li, J. Tian, J. Li, Simvastatin suppresses cell migration and invasion, induces G0/G1 cell cycle arrest and apoptosis in osteosarcoma cells, Int J Clin Exp Pathol 9(6) (2016) 5837-5848.
[205] S.-T. Wang, S.-W. Huang, K.-T. Liu, T.-Y. Lee, J.-J. Shieh, C.-Y. Wu, Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway, Cell death discovery 6(1) (2020) 1-11.
[206] C.-S. Yen, J.-C. Chen, Y.-F. Chang, Y.-F. Hsu, P.-T. Chiu, C. Shiue, Y.-F. Chuang, G. Ou, M.-J. Hsu, Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade, Scientific reports 6 (2016) 25082.
[207] S.W. Huang, I.T. Chyuan, C. Shiue, M.C. Yu, Y.F. Hsu, M.J. Hsu, Lovastatin- mediated MCF- 7 cancer cell death involves LKB1- AMPK- p38MAPK- p53- survivin signalling cascade, Journal of Cellular and Molecular Medicine 24(2) (2020) 1822-1836.
[208] F. Bai, Z. Yu, X. Gao, J. Gong, L. Fan, F. Liu, Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p, Aging (Albany NY) 11(10) (2019) 3198.
[209] N. Lee, N. Tilija Pun, W.J. Jang, J.W. Bae, C.H. Jeong, Pitavastatin induces apoptosis in oral squamous cell carcinoma through activation of FOXO3a, Journal of Cellular and Molecular Medicine (2020).
[210] N.A. Alhakamy, O.A. Ahmed, H.M. Aldawsari, M.Y. Alfaifi, B.G. Eid, A.B. Abdel-Naim, U.A. Fahmy, Encapsulation of Lovastatin in Zein Nanoparticles Exhibits Enhanced Apoptotic Activity in HepG2 Cells, International journal of molecular sciences 20(22) (2019) 5788.
[211] F. Kässner, T. Sauer, M. Penke, S. Richter, K. Landgraf, A. Körner, W. Kiess, N. Händel, A. Garten, Simvastatin induces apoptosis in PTEN‐haploinsufficient lipoma cells, International journal of molecular medicine 41(6) (2018) 3691-3698.

[212] T.F. Docrat, S. Nagiah, A. Krishnan, D.B. Naidoo, A.A. Chuturgoon, Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway, Chemico-biological interactions 287 (2018) 32-40.
[213] U.A. Fahmy, B.M. Aljaeid, Combined strategy for suppressing breast carcinoma MCF-7 cell lines by loading simvastatin on alpha lipoic acid nanoparticles, Expert opinion on drug delivery 13(12) (2016) 1653-1660.
[214] S.-T. Wang, H.J. Ho, J.-T. Lin, J.-J. Shieh, C.-Y. Wu, Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells, Cell death & disease 8(2) (2017) e2626-e2626.
[215] A.-R. Hwang, J.-H. Han, J.H. Lim, Y.J. Kang, C.-H. Woo, Fluvastatin inhibits AGE-induced cell proliferation and migration via an ERK5-dependent Nrf2 pathway in vascular smooth muscle cells, PloS one 12(5) (2017).
[216] J. Wang, Y. Tian, K. Xu, R. Fu, M. Niu, K. Zhao, Statins Regulate the Proliferation and Apoptosis of T-ALL Cells through the Inhibition of Akt Pathway, Zhongguo shi yan xue ye xue za zhi 26(2) (2018) 359-367.
[217] C.-H. Fu, T.-J. Lee, C.-C. Huang, P.-H. Chang, J.-W. Tsai, L.-P. Chuang, J.-H.S. Pang, Simvastatin inhibits the proliferation of HL-60 clone 15-derived eosinophils by inducing the arrest of the cell cycle in the G1/S phase, European journal of pharmacology 856 (2019) 172400.
[218] M. Afzali, M. Vatankhah, S.N. Ostad, Investigation of simvastatin-induced apoptosis and cell cycle arrest in cancer stem cells of MCF-7, Journal of cancer research and therapeutics 12(2) (2016) 725.
[219] P. Trojan, M. Bohatch-Junior, M. Otuki, F. Souza-Fonseca-Guimarães, P. Svidnicki, V. Nogaroto, D. Fernandes, E. Krum, G. Favero, Pravastatin induces cell cycle arrest and decreased production of VEGF and bFGF in multiple myeloma cell line, Brazilian Journal of Biology (AHEAD) (2016) 0-0.
[220] S. Chen, S. Dong, Z. Li, X. Guo, N. Zhang, B. Yu, Y. Sun, Atorvastatin calcium inhibits PDGF-ββ-induced proliferation and migration of VSMCs through the G0/G1 cell cycle arrest and suppression of activated PDGFRβ-PI3K-Akt signaling cascade, Cellular Physiology and Biochemistry 44(1) (2017) 215-228.
[221] J. Jang, J. Lee, J.H. Jang, C.W. Jung, S. Park, Anti-leukemic effects of simvastatin on NRAS G12D mutant acute myeloid leukemia cells, Molecular biology reports 46(6) (2019) 5859-5866.
[222] Y. Peng, G. He, L.X. Da Tang, Y. Wen, X. Miao, Z. Hong, H. Yao, C. Chen, S. Yan, L. Lu, Lovastatin inhibits Cancer stem cells and sensitizes to Chemo-and photodynamic therapy in nasopharyngeal carcinoma, Journal of Cancer 8(9) (2017) 1655.
[223] B. Putra, M.S.H. Wahyuningsih, E.N. Sholikhah, Cytotoxic activity of Simvastatin in T47D Breast Cancer Cell Lines and its effect on cyclin D1 Expression and Apoptosis, J. Med. Sci 49(1) (2017) 1-9.
[224] H.-Y. You, W.-J. Zhang, X.-M. Xie, Z.-H. Zheng, H.-L. Zhu, F.-Z. Jiang, Pitavastatin suppressed liver cancer cells in vitro and in vivo, OncoTargets and therapy 9 (2016) 5383.
[225] J.-L. Jouve, T. Lecomte, O. Bouché, E. Barbier, F.K. Akouz, G. Riachi, E.N. Khac, I. Ollivier-Hourmand, M. Debette-Gratien, R. Faroux, Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma, Journal of hepatology 71(3) (2019) 516-522.
[226] O. Alexander, A. Duygu, T. Erwin, M. Christoph, Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines, Scientific Reports (Nature Publisher Group) 10(1) (2020).

[227] S.A. Bandgar, N.R. Jadhav, A.S. Manjappa, A remarkable in vitro cytotoxic, cell cycle arresting and proapoptotic characteristics of low-dose mixed micellar simvastatin combined with alendronate sodium, Drug delivery and translational research (2020).
[228] N. Hagiwara, M. Watanabe, M. Iizuka-Ohashi, I. Yokota, S. Toriyama, M. Sukeno, M. Tomosugi, Y. Sowa, F. Hongo, K. Mikami, Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma, Cancer letters 431 (2018) 182-189.
[229] Z. Lin, Z. Zhang, X. Jiang, X. Kou, Y. Bao, H. Liu, F. Sun, S. Ling, N. Qin, L. Jiang, Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells, Oncotarget 8(11) (2017) 17833.
[230] T. Gehrke, A. Scherzad, S. Hackenberg, P. Ickrath, P. Schendzielorz, R. Hagen, N. Kleinsasser, Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro, International journal of oncology 51(3) (2017) 931-938.
[231] A. Al-Qatati, S. Aliwaini, Combined pitavastatin and dacarbazine treatment activates apoptosis and autophagy resulting in synergistic cytotoxicity in melanoma cells, Oncology letters 14(6) (2017) 7993-7999.
[232] B. Buranrat, W. Suwannaloet, J. Naowaboot, Simvastatin potentiates doxorubicin activity against MCF‐7 breast cancer cells, Oncology letters 14(5) (2017) 6243-6250.
[233] U.A. Fahmy, Augmentation of fluvastatin cytotoxicity against prostate carcinoma PC3 cell line utilizing alpha lipoic–ellagic acid nanostructured lipid carrier formula, AAPS PharmSciTech 19(8) (2018) 3454-3461.
[234] N. Li, X. Xie, Y. Hu, H. He, X. Fu, T. Fang, C. Li, Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy, American journal of translational research 11(3) (2019) 1255.
[235] S.H. Aliwaini, T.A. El-Bashiti, K.M. Mortaja, Pitavastatin Enhances Doxorubicin-induced Apoptosis in MCF7 Breast Cancer Cells, Jordan Journal of Biological Sciences 13(1) (2020).
[236] Y. Zhang, Y. Liu, J. Duan, H. Wang, Y. Zhang, K. Qiao, J. Wang, Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response, Cell Cycle 18(23) (2019) 3337-3350.
[237] X. Wu, M. Song, P. Qiu, K. Rakariyatham, F. Li, Z. Gao, X. Cai, M. Wang, F. Xu, J. Zheng, Synergistic chemopreventive effects of nobiletin and atorvastatin on colon carcinogenesis, Carcinogenesis 38(4) (2017) 455-464.
[238] R. Pantan, J. Tocharus, M. Phatsara, A. Suksamrarn, C. Tocharus, Synergistic effect of atorvastatin and cyanidin-3-glucoside against angiotensin II-mediated vascular smooth muscle cell proliferation and migration through MAPK and PI3K/Akt pathways, Archives of pharmacal research (2016) 1-12.
[239] W.-B. Zhong, Y.-C. Tsai, L.-H. Chin, J.-H. Tseng, L.-W. Tang, S. Horng, Y.-C. Fan, S.-P. Hsu, A synergistic anti-cancer effect of troglitazone and lovastatin in a human anaplastic thyroid cancer cell line and in a mouse xenograft model, International journal of molecular sciences 19(7) (2018) 1834.
[240] J.S. Kim, J. Turbov, R. Rosales, L.G. Thaete, G.C. Rodriguez, Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth, Gynecologic oncology 154(2) (2019) 432-440.
[241] M.A. Alqudah, H.T. Mansour, N. Mhaidat, Simvastatin enhances irinotecan-induced apoptosis in prostate cancer via inhibition of MCL-1, Saudi Pharmaceutical Journal 26(2) (2018) 191-197.

[242] S.-M. Kim, E.-J. Lee, J.H. Lee, W.M. Yang, D. Nam, J.-H. Lee, S.-G. Lee, J.-Y. Um, B.S. Shim, K.S. Ahn, Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-κB signalling pathway in human chronic myelogenous leukaemia, Pharmaceutical biology 54(10) (2016) 2050-2060.
[243] I.F. Kretzer, D.A. Maria, M.C. Guido, T.C. Contente, R.C. Maranhão, Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice, International journal of nanomedicine 11 (2016) 885.
[244] Y.C. Castellanos-Esparza, S. Wu, L. Huang, C. Buquet, R. Shen, B. Sanchez-Gonzalez, E.A. García Latorre, O. Boyer, R. Varin, L.A. Jiménez-Zamudio, Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells, International journal of oncology 52(4) (2018) 1246-1254.
[245] A.B. Ibrahim, H.F. Zaki, W. Wadie, M.M. Omran, S.A. Shouman, Simvastatin Evokes An Unpredicted Antagonism For Tamoxifen In MCF-7 Breast Cancer Cells, Cancer Management and Research 11 (2019) 10011.
[246] J.Y. Lee, M.-S. Kim, J.E. Ju, M.S. Lee, N. Chung, Y.K. Jeong, Simvastatin enhances the radiosensitivity of p53- deficient cells via inhibition of mouse double minute 2 homolog, International Journal of Oncology 52(1) (2017) 211-218.
[247] B. Chen, M. Zhang, D. Xing, Y. Feng, Atorvastatin enhances radiosensitivity in hypoxia-induced prostate cancer cells related with HIF-1α inhibition, Bioscience reports 37(4) (2017).
[248] Z.-S. Wang, H.-R. Huang, L.-Y. Zhang, S. Kim, Y. He, D.-L. Li, C. Farischon, K. Zhang, X. Zheng, Z.-Y. Du, Mechanistic study of inhibitory effects of metformin and atorvastatin in combination on prostate cancer cells in vitro and in vivo, Biological and Pharmaceutical Bulletin 40(8) (2017) 1247-1254.
[249] Z. Wang, L. Zhang, Z. Wan, Y. He, H. Huang, H. Xiang, X. Wu, K. Zhang, Y. Liu, S.J.P. Goodin, O. Research, Atorvastatin and caffeine in combination regulates apoptosis, migration, invasion and tumorspheres of prostate cancer cells, 26(1) (2020) 209-216.
[250] K. Xia, P. Zhang, J. Hu, H. Hou, M. Xiong, J. Xiong, N. Yan, Synergistic effect of receptor-interacting protein 140 and simvastatin on the inhibition of proliferation and survival of hepatocellular carcinoma cells, Oncology letters 15(4) (2018) 4344-4350.
[251] K. ŚRODA-POMIANEK, K. Michalak, A. PALKO-ŁABUZ, A. Uryga, B. SZCZĘŚNIAK-SIĘGA, O. WESOŁOWSKA, Simvastatin Strongly Augments Proapoptotic, Anti-inflammatory and cytotoxic activity of oxicam derivatives in doxorubicin-resistant colon cancer cells, Anticancer research 39(2) (2019) 727-734.
[252] A.B. Ibrahim, H.F. Zaki, W.W. Ibrahim, M.M. Omran, S.A. Shouman, Evaluation of tamoxifen and simvastatin as the combination therapy for the treatment of hormonal dependent breast cancer cells, Toxicology Reports 6 (2019) 1114-1126.
[253] K. Okubo, M. Isono, K. Miyai, T. Asano, A.J.C.s. Sato, Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells, 111(1) (2020) 112.
[254] Y.-H. Chen, Y.-C. Chen, C.-C. Lin, Y.-P. Hsieh, C.-S. Hsu, M.-C.J.C.M. Hsieh, Research, Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo, 12 (2020) 4645.
[255] V.S. Desai, E. Buchhalter, M. Cabanzo, A. Tiwari, G. Kaushal, J.C. Lai, A. Bhushan, Differential effects of combination treatment of biochanin A and statins on glioblastoma multiforme cell proliferation and cell metabolism, AACR, 2019.
[256] X. Mo, Z. Zheng, Y. He, H. Zhong, X. Kang, M. Shi, T. Liu, Z. Jiao, Y. Huang, Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-

mediated biomimetic codelivery of simvastatin/fenretinide, Journal of Controlled Release 287 (2018) 12-23.
[257] C. Cemeus, T.T. Zhao, G.M. Barrett, I.A. Lorimer, J. Dimitroulakos, Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status, Journal of neuro-oncology 90(1) (2008) 9-17.
[258] D. Gabrys, A. Doerfler, M. Baumann, 231 Combination of lovastatin and X-Irradiation decreases clonogenicity, cell number, and induces changes in the cell cycle of U87 human malignant glioma cells, Radiotherapy and Oncology 78 (2006) S82.
[259] J.H. Tapia-Perez, R. Preininger, E. Kirches, A. Reinhold, J. Butzmann, S. Prilloff, C. Mawrin, T. Schneider, Simultaneous administration of statins and pioglitazone limits tumor growth in a rat model of malignant glioma, Anticancer research 36(12) (2016) 6357-6365.

**Figure legends**

**Figure 1.** The mechanism of action of statins in cancer. Downstream products of the mevalonate pathway are essential for the prenylation of cellular proteins Ras, Rho, and Rac1, as small GTPases, which are critical for regulating cell growth and the cell cycle, angiogenesis, apoptosis, oxidative damage, invasion, and survival.

**Figure 2.** Potential apoptosis-inducing effects of statins in cancer.

**Figure 3.** The schematic representation of molecular mechanisms of statins in GBM.


Acetyl CoA
HMG CoA
HMG-CoA reductase
STATINS
Indirectly
Inflammatory cytokines
(IL-2, IL-6, IL-12)
Mevalonate
Indirectly
Isopentenyl-PP
Genes involved in angiogenesis and inflammation
(VEGF, PDGF, IGF, FGF, V-CAM)
Geranyl-PP
Farnesyl-PP
Farnesylated protein
Ras
Cell growth and angiogenesis
Cell cycle and apoptosis inhibition
Cholesterol
Steroid synthesis
Geranylated protein
Rac1
Oxidative damage
Geranylgeranyl-PP
Geranylated protein
RhoA
Inflammation, cell proliferation, cell motility, migration, and invasion


STATINS
Apoptosis initiation
Inhibition of Ras farnesylation
Decreased Bcl-2
Caspase activation
Impairment of RhoA/Rac-1 activity
DNA fragmentation
Modulation of AKT/FOXO1
Suppression of the NF-κB
ROS generation
Regulating Akt, ERK, and p38 MAPK
Suppressing survivin expression
Deactivating PI3K/Akt/mTOR


STATINS
Indirectly
Indirectly
VEGF, E-selectin, and MMPs hyperactivation
TGF-β
Migration and invasion
Angiogenesis and micrometastasis
STATINS
GPCR
DR
Cell cycle arrest (G1- and S-phase)
MCL-1
Bcl-2
Bcl-xL
Ras
Rho
PI3K
Raf
AKT
MEK
ERK
Bax
Caspase-9
Procaspase-8
FADD
Cell proliferation
Caspase-3
Active caspases-8/-10
mTORC1
Caspase-3
Mevalonate pathway
Autophagy
Apoptosis
EMT outgrowth
Apoptosis
Negative feedback
STATINS
Nucleus
HMGCR